USRE33161E - Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements - Google Patents

Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements Download PDF

Info

Publication number
USRE33161E
USRE33161E US07/163,014 US16301488A USRE33161E US RE33161 E USRE33161 E US RE33161E US 16301488 A US16301488 A US 16301488A US RE33161 E USRE33161 E US RE33161E
Authority
US
United States
Prior art keywords
iaddend
iadd
slurry
paste
cement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/163,014
Inventor
Walter E. Brown
Laurence C. Chow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Dental Association Health Foundation
Howmedica Osteonics Corp
Original Assignee
American Dental Association Health Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/539,740 external-priority patent/US4518430A/en
Application filed by American Dental Association Health Foundation filed Critical American Dental Association Health Foundation
Priority to US07/163,014 priority Critical patent/USRE33161E/en
Application granted granted Critical
Publication of USRE33161E publication Critical patent/USRE33161E/en
Assigned to STRYKER TECHNOLOGIES CORPORATION reassignment STRYKER TECHNOLOGIES CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOWMEDICA INC.
Assigned to BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION reassignment BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION SECURITY AGREEMENT Assignors: STRYKER CORPORATION, STRYKER FAR EAST, INC.
Assigned to BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION reassignment BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOWMEDICA CORPORATION, HOWMEDICA LEIBINGER, INC., SMD CORPORATION, STRYKER CORPORATION, STRYKER FAR EAST, INC., STRYKER FOREIGN HOLDCO INC., STRYKER IMPLANTS INC., STRYKER INTERNATIONAL INC., STRYKER PUERTO RICO INC., STRYKER SALES CORPORATION, STRYKER TECHNOLOGIES CORPORATION
Assigned to STRYKER CORPORATION, STRYKER TECHNOLOGIES CORPORATION, HOWMEDICA OSTEONICS CORPORATION, STRYKER SALES CORPORATION, HOWMEDICAL LEIBINGER, INC., PHYSIOTHERAPY ASSOCIATES, INC., SMD CORPORATION, STRYKER FAR EAST, INC., STRYKER FOREIGN HOLDCO, INC., STRYKER INTERNATIONAL, INC., STRYKER PUERTO RICO INC. reassignment STRYKER CORPORATION RELEASE OF SECURITY INTEREST Assignors: BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION)
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/02Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/15Compositions characterised by their physical properties
    • A61K6/17Particle size
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/60Preparations for dentistry comprising organic or organo-metallic additives
    • A61K6/69Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/831Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
    • A61K6/838Phosphorus compounds, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/849Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
    • A61K6/876Calcium oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24Phosphorous; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • C01B25/32Phosphates of magnesium, calcium, strontium, or barium
    • C01B25/327After-treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/594Mixtures of polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/12Materials or treatment for tissue regeneration for dental implants or prostheses

Definitions

  • This invention relates to certain combinations of sparingly soluble calcium phosphates that are unique in their application as remineralizers of caries lesions in dental enamel and partially demineralized dentin and cementum and in their application as dental cements.
  • the present invention When used as a remineralizer the present invention not only prevents tooth decay, but can also restore the lesions caused by dental caries.
  • the dental cements of the present invention have a variety of dental applications, but are most useful where contact between the cement and living tissue is required.
  • the supersaturated solutions or slurries used for remineralization experiments have been prepared from a single form of calcium phosphate.
  • the calcium and phosphate ions in the form of precipitated hydroxyapatite remineralize the lesion.
  • these solutions are impractical for use on patients for several reasons.
  • the amount of calcium and phosphate ions available for remineralization in these supersaturated solutions is too low. It takes approximately 10,000 unit volumes of the usual supersaturated solution to produce one unit volume of mineral.
  • remineralization by this method requires both an excessive volume of fluid and an excessive number of applications.
  • remineralization may stop before the lesion is completely remineralized due to build up of the remineralized tooth material in or on the outer layer of the tooth's surface. This build up occurs when the rate of remineralization is too fast and prevents the diffusion of the mineral into the deeper regions of the lesion, thus thwarting the full remineralization of the tooth.
  • a calcium phosphate dental cement should provide a non-irritating cement capable of setting to a hard consistency and, when desired, remineralizing the dental tissue it contacts. Such a cement would be of great benefit, for example, as a root canal or root surface cement.
  • the potential for application of dental remineralization is vast. Approximately 5 ⁇ 10 8 cavities are filled each year. If these half billion caries lesions were remineralized rather than being filled as cavities, the general dental health would be increased substantially, since remineralization results in a whole tooth.
  • the present invention seeks to provide remineralization compositions and methods that can be practically applied under a dentist's care and thereby replace the need for filling of cavities.
  • the present invention relates to compositions for remineralizing caries lesions.
  • the invention concerns a combination of Ca 4 (PO 4 ) 2 O (tetracalcium phosphate) and at least one other sparingly soluble calcium phosphate solid in equilibrium or quasi equilibrium with a dilute aqueous solution such that both calcium phosphates are present in excess and form a slurry.
  • the other calcium phosphates that may be used are CaHPO 4 .2H 2 O (dicalcium phosphate dihydrate or brushite), CaHPO 4 (monetite), Ca 8 H 2 (PO 4 ) 6 .5H 2 O (octacalcium phosphate), ⁇ --Ca 3 (PO 4 ) 2 , ⁇ --Ca 3 (PO 4 ) 2 (tricalcium phosphates), and tricalcium phosphates modified by the addition of protons or up to approximately 10% magnesium by weight (whitlockite). All combinations of these calcium phosphates can precipitate hydroxyapatite according to the present invention.
  • the two calcium phosphates must be in near equilibrium with the same saturated solution; furthermore, the saturated solution must be supersaturated with respect to hydroxyapatite. If these conditions are met, the above combinations of calcium phosphates will react to form hydroxyapatite. Since the two calcium phosphates are present in excess, the solution will remain supersaturated with respect to hydroxyapatite and will continue to precipitate this basic constituent of tooth and bone.
  • Another significant advantage of the present invention is that the combination of sparingly soluble calcium phosphates stabilizes the pH of the system near the point of equilibrium. This prevents wide swings in pH that might injure the dental enamel or other tissue. A stable pH also permits hydroxyapatite to continue precipitating, since hydroxyapatite will not precipitate at a low pH. Furthermore, the pH of the singular point may be altered by the addition of calcium or phosphate containing compounds to the slurry. This allows the dentist to select the most beneficial pH for remineralization.
  • Another advantage of the present invention is that the rate of mineralization may be adjusted to the needs of the particular lesion.
  • the addition of simple fluoride compounds will increase the rate of mineralization.
  • high molecular weight crystal growth inhibitors may be added to slow mineralization. These latter compounds facilitate the remineralization of the subsurface of a caries lesion by inhibiting the remineralization of the outside surface of the tooth. This allows the hydroxyapatite ions to diffuse into the lesion's subsurface and completely remineralize the cavity.
  • the present invention provides compositions for the remineralization of caries lesions that are practical for clinical use due to their large remineralization capacities and stable pH's.
  • the rate and depth of remineralization may be selected by the dentist, thereby giving substantial flexibility to the remineralization process.
  • the present invention also concerns compounds useful as dental cements.
  • the same combinations of calcium phosphates described above may be combined in a paste, rather than a slurry, and allowed to harden.
  • the resulting cements are similar in composition to tooth and bone material and, therefore, are fully compatible with dental tissue.
  • the cements of the present invention may be used in any application for which conventional dental cements are suitable, the cements of the present invention are particularly helpful where contact with living tissue is required.
  • these cements provide the unique combination of remineralizing properties and hardening characteristics that would be especially desirable for a root canal or root surface cement because they are compatible with, protect and remineralize the sensitive surfaces of exposed roots.
  • FIG. 1 is a plot of the solubility isotherms of Ca 4 (PO 4 ) 2 O; CaHPO 4 .2H 2 O; CaHPO 4 ; Ca 8 H 2 (PO 4 ) 6 .5H 2 O; ⁇ --Ca 3 (PO 4 ) 2 ; and Ca 5 (PO 4 ) 3 OH at 25° C. in the ternary system of Ca(OH) 2 ; H 3 PO 4 ; and H 2 O.
  • the sparingly soluble calcium phosphates that are relatively stable at ambient temperatures and are, therefore, available for use in the inventive remineralizing slurries and cements include CaHPO 4 .2H 2 O; CaHPO 4 ; Ca 8 H 2 (PO 4 ) 6 .5H 2 O; ⁇ --Ca 3 (PO 4 ) 2 ; ⁇ --Ca 3 (PO 4 ) 2 ; tricalcium phosphates modified by protons or up to approximately 10% magnesium by weight; and Ca 4 (PO 4 ) 2 O.
  • Each of these calcium phosphates has a characteristic solubility behavior that may be represented by a plot of the total concentration of calcium ions at the point of saturation verus the pH of the solution at a constant temperature. (A plot of the total concentration of phosphate ions versus pH would be equivalent for the purposes of the present invention because the concentrations of phosphate and calcium ions in solution are linked.) The resulting curve is called an isotherm.
  • FIG. 1 is a plot of the solubility isotherms for six calcium phosphates in the ternary system comprising Ca(OH) 2 , H 3 PO 4 and H 2 O at 25° C.
  • the y-axis of FIG. 1 represents the total concentration of calcium ions in solution in moles per liter, while the x-axis represents pH.
  • the isotherm for Ca 8 H 2 (PO 4 ) 6 .5H 2 O is based on the solubility product disclosed on Moreno et al, "Stability of Dicalcium Phosphate Dihydrate in Aqueous Solutions and Solubility of Octacalcium Phosphate", Soil Sci. Soc. Am. Proc. 21: 99-102 (1960), while the isotherm of Ca 4 (PO 4 ) 2 O is based on the approximate value of the solubility product calculated by the inventors.
  • the inventive combinations of calcium phosphates must contain Ca 4 (PO 4 ) 2 O in order to possess the desired remineralization properties.
  • the singular point of the two calcium phosphates must lie above the isotherm for hydroxyapatite. This insures that a solution that is saturated with respect to the two calcium phosphates at their singular point will also be supersaturated with respect to hydroxyapatite. Thus, hydroxyapatite can precipitate out of the solution and be available for remineralization.
  • the singular point for the pair of calcium phosphates should preferably not lie too far above the isotherm for CaHPO 4 .2H 2 O, since the singular point of such a combination might be too unstable for use as a remineralizer or cement. Therefore, although ⁇ --Ca 3 (PO 4 ) 2 and Ca 8 H 2 (PO 4 ) 6 .5H 2 O have intersecting isotherms, their singular point lies far above the isotherm for CaHPO 4 .2H 2 O and is unsuitable.
  • the circles in FIG. 1 define singular point compositions for the various pairs of solids in solution.
  • the following combinations of calcium phosphates are definitely available as remineralizers and cements according to the present invention: CaHPO 4 .2H 2 O with Ca 4 (PO 4 ); CaHPO 4 with Ca 4 (PO 4 ) 2 O; Ca 4 (PO 4 ) 2 O with Ca 8 H 2 (PO 4 ) 6 .5H 2 O; and Ca 4 (PO 4 ) 2 O with ⁇ --Ca 3 (PO 4 ) 2 .
  • the isotherms of the modified tricalcium phosphates may define additional inventive compositions.
  • a singular point composition has such desirable properties as a remineralizer and cement is that it resists changes in the pH or composition of the solution by driving itself back to the singular point whenever the composition or pH changes. For example, if two calcium phosphates that possess a singulr point were present in excess in a solution that was more acidic than the pH of the singular point, the more basic phosphate would dissolve and cause the more acidic phosphate to precipitate. This process would continue until the pH and the composition were forced back to the singular point, where the two calcium phosphates present in excess would both be in equilibrium with the solution and neither would precipitate out of solution. The reverse process would occur if the composition started at a point more basic than the singular point pH.
  • the composition of the solution cannot rise above the isotherm of the more soluble salt or fall below the isotherm of the less soluble salt. Furthermore, the solution will only be in equilibrium at the singular point. However, the precipitation of a third salt, such as hydroxyapatite, may drive the composition in the direction of the third salt's isotherm. The degree of deviation depends upon the relative rates of dissolution and precipitation of the three salts.
  • any of the remaining calcium phosphates that are more acidic than hydroxyapatite can react directly with tetracalcium phosphate to form hydroxyapatite.
  • any of the remaining calcium phosphates that are more acidic than hydroxyapatite can react directly with tetracalcium phosphate to form hydroxyapatite.
  • Ca 4 (PO 4 ) 2 O is a necessary ingredient for the inventive compositions to be effective remineralizing agents.
  • inventive combinations may also be used as densitizing agents due to their remineralization properties. Since clogging of the dental tubules reduces the pain sensitivity of the dental tissue, the remineralization promoted by the inventive compositions also tends to desensitize the remineralized tissue.
  • the pH range of the inventive system may be predetermined by choosing a pair of calcium phosphates with an appropriate singular point pH. For example, if a pH around 7.5 is desired, one could use the combination of CaHPO 4 .2H 2 O and Ca 4 (PO 4 ) 2 O.
  • the pH of any slurry or paste may be further altered by the addition of up to approximately 10% by weight of simple calcium or phosphate containing compounds. These compounds change the pH of the singular point by altering the Ca/P ratio of the solution.
  • an acidic compound such as HCl, CaCl 2 , or Ca(C 2 H 3 O 2 ) 2
  • an acidic compound such as HCl, CaCl 2 , or Ca(C 2 H 3 O 2 ) 2
  • HCl, CaCl 2 , or Ca(C 2 H 3 O 2 ) 2 will increase the ionic activity of Ca 2+ , increase the Ca/P ratio of the singular point and cause the singular point to move to a lower pH.
  • suitable base and phosphate containing compounds are NaH 2 PO 4 and (NH 4 )H 2 PO 4 .
  • the rate of remineralization may also be adjusted.
  • the addition of simple or complex fluoride compounds such that the fluoride content of the slurry or paste is up to approximately 3.8% by weight will increase the rate of precipitation of hydroxyapatite and decrease solubility, thereby providing a control on the body's ability to resorb the material.
  • Examples of possible fluoride additives are CaF 2 , SnF 2 , NaF, Na 2 SiF 6 , and Na 2 PO 3 F. Though rapid mineralization is beneficial under some circumstances, it may cause the remineralization of the outside surface of an incipient caries lesion and prevent the remineralization of the subsurface region of the lesion.
  • a moderately slow remineralization rate would allow all parts of the lesion to be healed.
  • the particular calcium phosphates used will affect the rate of remineralization.
  • particle size is a factor since as particle size increases, the rate of mineralization decreases.
  • the particle size for remineralization slurries should be greater than 5 um.
  • a slow remineralizing slurry could be applied to the tooth by means of a bite block sponge, periodontal pack, cement or rigid gel.
  • All of the combinations of calcium phosphates described above may be used as dental cements.
  • the two main differences between the inventive remineralizers and the inventive cements are particle size and solid-to-liquid ratio.
  • the selected calcium phosphates should be ground to a finer particle size, preferably less than 5 ⁇ m. Additionally, calcium phosphate particles are combined with much less solution so that a paste is formed rather than a slurry. The paste then hardens to a bone-like consistency.
  • Porous cements that are especially useful as bone implants or protheses may be prepared by combining the calcium phosphates with a highly water soluble material, such as granular sugar, and subjecting the mixture to pressure sufficient to form a compact mass.
  • the water necessary for the inventive reaction is usually contained in the calcium phosphates themselves. However, a small amount of water may be added to the mixture before pressure is applied in order to facilitate the setting of the cement. The resulting mass is then placed into hot water such that the highly water soluble material is removed.
  • a porous cement remains that is readily permeated by organic bone tissue.
  • glycerin In order to improve the flow properties of the inventive dental cement pastes, it is desirable to incorporate glycerin, ethanol, glycol or some other nontoxic organic solvent into the paste. Since the cement mixture ingredients are inert to glycerin, a nonaqueous paste containing Ca 4 (PO 4 ) 2 O and another calcium phosphate in glycerin will not harden or set. Thus, such a water free glycerin-based paste can be stably preserved in a moisture-free sealed tube for several months. However, when the glycerin paste is exposed to humid air or to water, setting occurs quite rapidly.
  • the glycerin serves as a vehicle for the inventive combinations and produces desirable flow properties for the paste such that the paste may be injected or delivered through a fine orifice or tubing.
  • glycerin aids such operations as the delivery of the inventive pastes into root canals using a one millimeter syringe fitted with an 18 gauge needle. The glycerin eventually leaches out of the set or hardened cement.
  • the cements of the present invention may be used in place of any of the cements known in the prior art as: (i) cavity bases and liners to protect the pulp; (ii) materials for capping exposed pulps; (iii) materials to replace or promote regeneration of bone mineral lost due to periodontal disease; (iv) direct filling materials that have physical properties similar to enamel and are adhesive to enamel and dentin; (v) a cement to build up alveolar ridges in edentulous patients; (vi) an endodontic filling material for root canals; (vii) a material to cement retention pins; (viii) a material for filling sockets after a tooth extraction; (ix) a replacement of bone that has been removed surgically or lost due to trauma; (x) a cement for implanting or replanting teeth; (xi) a luting cement in densitry and orthopedic surgury; (xii) an investment mold material; (xiii) a material which will promote bone mineral growth in its vicinity; (xi
  • inventive cements are fully compatible with living tissue, they are especially advantageous where contact with dental tissue is necessary. in addition, the cements possess remineralization capabilities. Thus, the discussion above with respect to the use of the inventive compositions as remineralizers is fully applicable to their use as cements.
  • the strength and hardness of the present cements can be controlled by the particle size of the calcium phosphates, the presence of hydroxyapatite or Ca 5 (PO 4 ) 3 F (fluorapatite) as seed or matrix crystals, and by the use of crystal habit modifiers. These last compounds promote the growth of more needle-like apatitic crystals in the cement. It is believed that a particle size of 1 ⁇ m would result in a very strong cement.
  • the setting time of the present cements may be reduced by adding a sizable amount of hydroxyapatite or fluorapatite seed crystals to the paste as these compounds facilitate crystal formation. This may also increase the hardness of the cement and minimize shrinkage or expansion during set.
  • the addition of Ca 5 (PO 4 ) 2 SiO 4 or silicocarnotite may also improve the setting properties of the cements.
  • Such expansion may be achieved by the addition of ⁇ --Ca 3 (PO 4 ) 2 or up to 1% by weight of crystal habit modifiers, such as Mg 2+ , Sr 2+ , citrate, phosphates, carbonate, polyphosphates, sucrose phosphate and phosphocitrate. These modifiers adsorb onto the specific sites of the crystal surfaces during growth, thereby affecting the morphology of the crystals. Additionally, appropriate combinations of varying or "gap-graded" particle sizes would promote setting expansion.
  • crystal habit modifiers such as Mg 2+ , Sr 2+ , citrate, phosphates, carbonate, polyphosphates, sucrose phosphate and phosphocitrate.
  • Ca 4 (PO 4 ) 2 O and another calcium phosphate having a singular point with Ca 4 (PO 4 ) 2 O at an appropriate pH are selected. Their singular point should not lie too far above the isotherm for CaHPO 4 .2H 2 O and must lie above the isotherm for hydroxyapatite.
  • the calcium phosphates selected may be prepared by the methods described in McDowell et al, "Solubility Study of Calcium Hydrogen Phosphate. Ion-Pair Formation", Inorg. Chem.
  • the calcium phosphates may be in crystalline, cryptocrystalline, finely divided, or amorphous form.
  • each of the selected, solid calcium phosphates is then ground to the desired particle size.
  • the particle size should be greater than 5 ⁇ m, since this size prolongs the remineralization potential of the slurry by slowing the remineralization rate. Larger particle size both slows the reaction rate and retards the setting or hardening of the slurry.
  • the ground calcium phosphates are then mixed in excess in a dilute aqueous solution that is either slightly acidic or slightly basic to form a slurry.
  • gelling agents such as carboxylmethyl cellulose may be added to the slurry such that an aqueous gel is formed.
  • appropriate acidic solutions are water and H 3 PO 4 or HCl
  • appropriate basic solutions are water and Ca(OH) 2 or KOH.
  • the slurry may be applied to the affected area by means of a bite block sponge, periodontal pack, cement, or rigid gel. Also the slurry may be applied by burnishing, spatulation or packing and covering by various mechanical means. Additionally, the slurry may be allowed to harden and thereby act as its own cement for holding the remineralizer against the afflicted area.
  • the above remineralizing combinations may be incorporated into chewing gum formulations by blending the solid and liquid phases with a chewing gum base in the manner practiced in the industry.
  • the solid and liquid phases may be combined with the common ingredients of toothpaste.
  • the particle size of the calcium phosphates should be such as to avoid grittiness.
  • Another alternative is to apply the above remineralizing combinations as a dry powder. The remineralizing properties of the powder are then activated by the addition of an appropriate aqueous solvent, such as water or saliva.
  • fluoride compounds such as CaF 2 , SnF 2 , NaF, Na 2 SiF 6 , or Na 2 PO 3 F
  • fluoride compounds such as CaF 2 , SnF 2 , NaF, Na 2 SiF 6 , or Na 2 PO 3 F
  • calcium and phosphate containing compounds such as CaCl 2 , Ca(C 2 H 3 O 2 ) 2 , NaH 2 PO 4 , or (NH 4 )H 2 PO 4 , may be added to modify the Ca/P ratio and pH of the solution's singular point.
  • high molecular weight crystal growth inhibitors may be added to facilitate the complete remineralization of the subsurface caries lesions.
  • a gelling agent may be added.
  • Ca 4 (PO 4 ) 2 O and CaHPO 4 .2H 2 O are ground to an approximate mean particle size of 40 ⁇ m.
  • Two grams of an equimolar mixture of the two solids is combined with 20 ml of a 5 mM H 3 PO 4 solution and mixed to form a slurry.
  • the slurry is then placed on a caries lesion by means of a bite block sponge. This slurry will maintain a pH in the vicinity of 7.4 and precipitate hydroxyapatite for almost one week.
  • Ca 4 (PO 4 ) 2 O and at least one other calcium phosphate selected from the group consisting of CaHPO 4 .2H 2 O, CaHPO 4 , Ca 8 H 2 (PO 4 ) 6 .5H 2 O, ⁇ --Ca 3 (PO 4 ) 2 , ⁇ --Ca 3 (PO 4 ) 2 , and modified Ca 3 (PO 4 ) 2 are ground to a uniform particle size of less than 5 ⁇ m so that the setting time will be reasonable. If some setting expansion is required, "gap-graded" particle sizes may be used.
  • the calcium phosphates are then combined with the dilute aqueous solutions of Example 1 to form a paste. This paste is then applied by an appropriate means to the affected area.
  • the paste may be applied by injection or packed with a plugger.
  • the calcium phosphates are combined with a nonaqueous medium such as glycerin, ethanol or glycol to form a paste. These nonaqueous pastes will harden upon exposure to the dilute aqueous solutions of Example 1 or humid air.
  • the combined calcium phosphates may be applied as a dry powder that will form a hardenable paste upon contact with an appropriate aqueous solvent such as water or saliva.
  • the additives described in Example 1 may be added to the liquid or solid phase.
  • crystal habit modifiers may be added to induce more needle-like growth of apatitic crystals.
  • the setting time for a given cement may be reduced by adding hydroxyapatite or fluorapatite seed crystals. The inclusion of fluoride compounds will further reduce the setting time. Silicocarnotite may improve the setting properties of the cement.
  • Setting expansion and shrinkage may be reduced by adding a sizeable amount of hydroxyapatite to the paste. Conversely, some setting expansion may be encouraged by the addition of ⁇ --Ca 3 (PO 4 ) 2 or crystal habit modifiers.
  • Specimens 1-5 shown in Table I were prepared as follows. The two calcium phosphates and hydroxyapatite seed were all ground to a mean particle size of 5 ⁇ m. One gram of a mixture containing equimolar amounts of the two calcium phosphates and the appropriate weight percent of Ca 5 (PO 4 ) 3 OH was mixed with 0.5 ml of the appropriate H 2 PO 4 solution. All of the specimens were stirred into pastes, allowed to harden, and were soaked in H 2 O at 37° C. for twenty-four hours. The compressive strengths in pounds per square inch were then determined as shown in Table I.
  • Specimens 6-9 shown in Table II were prepared by grinding Ca 4 (PO 4 ) 2 O, CaHPO 4 .2H 2 O, and Ca 5 (PO 4 ) 3 OH to a mean particle size of 5 ⁇ m.
  • One gram of a mixture containing equimolar amounts of Ca 4 (PO 4 ) 2 O and CaHPO 4 .2H 2 O and the appropriate weight percent of Ca 5 (PO 4 ) 3 OH was mixed with 0.5 ml of 20 mM H 3 PO 4 to form a paste. This paste was then allowed to harden.
  • the setting times as a function of apatite seed content are shown in Table II.
  • Ca 4 (PO 4 ) 2 O and CaHPO 4 .2H 2 O are ground to a mean particle size of 5 ⁇ m.
  • Two grams of a mixture containing equimolar amounts of the two calcium phosphates and 0.5 gram of granular sugar (or another highly water soluble material) are mixed and placed in a mold. Usually addition of water to the mixture is not needed but a small amount may be added in some instances to facilitate the setting reaction. Up to 80,000 pounds per square inch of pressure is applied to the cement mixture using a press for two minutes.
  • the specimen which is made into a compact mass by the process, is placed in boiling water to extract the water soluble granules and to complete the setting process.
  • the resulting porous materials can be used as protheses which can be invaded more readily by organic bone tissue.

Abstract

Dental restorative compositions containing a mixture of Ca4 (PO4)2 O and at least one different calcium phosphate.

Description

The invention described herein was made in the course of research partially supported by a grant from the National Institute of Dental Research.
This application is a continuation-in-part of the copending application Ser. No. 539,740, filed Oct. 6, 1983, now U.S. Pat. No. 4,518,430, which in turn is a continuation-in-part of the application, Ser. No. 373,157, filed on Apr. 29, 1982, now abandonded.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to certain combinations of sparingly soluble calcium phosphates that are unique in their application as remineralizers of caries lesions in dental enamel and partially demineralized dentin and cementum and in their application as dental cements. When used as a remineralizer the present invention not only prevents tooth decay, but can also restore the lesions caused by dental caries. The dental cements of the present invention have a variety of dental applications, but are most useful where contact between the cement and living tissue is required.
2. Description of the Prior Art
When an incipient lesion or cavity develops on the surface of a tooth, the dentist traditionally fills the cavity that forms. This procedure may prevent the decay from spreading further, but does not restore the tooth to its original state. A considerable amount of research, however, has recently been directed to the remineralization of incipient dental lesions. The object of remineralization is to deposit Ca5 (PO4)3 OH, known as hydroxyapatite, on the caries lesion such that the dental enamel incorporates the hydroxyapatite into its structure at the point of lesion. (Tooth and bone minerals are impure forms of hydroxyapatite). Thus, remineralization prevents further tooth decay and restores the tooth.
Remineralization of tooth enamel has been carried out experimentally both in vivo and in vitro. These studies have concentrated on the remineralizing properties of saliva and synthetic solutions supersaturated with respect to hydroxyapatite. Two recent articles that give a good overview of this research are Briner et al, "Significance of Enamel Remineralization", J. Dent. Res. 53:239-243 (1974); and "Silverstone, "Remineralization Phenomena", Caries Res. 11 (Supp. 1): 59-84 (1977). Additional experimental work in the areas of remineralization of calcium phosphate biomaterials may be found in Gelhard et al, "Rehardening of Artificial Enamel Lesions in vivo", Caries Res. 13: 80-83 (1979); Hiatt et al, "Root Preparation I. Obduration of Dentinal Tubules in Treatment of Root Hypersensitivity", J. Periodontal. 43: 373-380 (1972); LeGeros et al, "Apatitic Calcium Phosphates: Possible Dental Restorative Materials", IADR Abstract No. 1482 (1982); Pickel et al, "The Effect of a Chewing Gum Containing Dicalcium Phosphate on Salivary Calcium and Phosphate", Ala. J. Med. Sci. 2: 286- 287 (1965); Zimmerman et al, "The Effect of Remineralization Fluids on Carious Lesions in vitro", IADR Abstract No. 282 (1979); and U.S. Pat. Nos. 3,679,360 (Rubin) and 4,097,935 (Jarcho).
Generally, the supersaturated solutions or slurries used for remineralization experiments have been prepared from a single form of calcium phosphate. When a caries lesion is flooded with one of these supersaturated solutions, the calcium and phosphate ions in the form of precipitated hydroxyapatite remineralize the lesion. However, these solutions are impractical for use on patients for several reasons. First, the amount of calcium and phosphate ions available for remineralization in these supersaturated solutions is too low. It takes approximately 10,000 unit volumes of the usual supersaturated solution to produce one unit volume of mineral. Thus, remineralization by this method requires both an excessive volume of fluid and an excessive number of applications. The supersaturated solutions are inherently limited in this respect because they cannot maintain their supersaturated state. When the hydroxyapatite precipitates out to the point where the solution is no longer supersaturated, new supersaturated solution must be introduced or the remineralization process stops.
An example of another kind of problem is described in Levine, "Remineralization of Natural Carious Lesions of Enamel in vitro", Brit. Dent. J., 137: 132-134 (1974), where a phosphate buffer solution saturated with respect to CaHPO4.2H2 O (dicalcium phosphate dihydrate or brushite) and containing some fluoride was applied to dental enamel. To effect complete mineralization, exposure to the solution for three minutes every hour for 24 hours was necessary. Though the article suggested that this exposure could be achieved by use of two minute mouth rinses twice daily over the course of a year, this was admitted by the author to be an impractical procedure.
Another problem with single calcium phosphate slurries is that as the hydroxyapatite precipitates out of solution, the pH of the solution changes. Unless the old solution is removed from contact with the tooth material, the solution may become too acidic or alkaline and damage the dental tissue.
Another problem with known remineralization techniques is that the remineralization may stop before the lesion is completely remineralized due to build up of the remineralized tooth material in or on the outer layer of the tooth's surface. This build up occurs when the rate of remineralization is too fast and prevents the diffusion of the mineral into the deeper regions of the lesion, thus thwarting the full remineralization of the tooth.
There is a need for a method of remineralizing dental enamel that does not require excessive amounts of solution and inordinately long or frequent exposure times. Furthermore there is a need for a remineralization solution or slurry that can maintain a relatively constant pH and remain in a supersaturated state so that hydroxyapatite may be precipitated for a substantial period of time.
In the area of dental cements, the prior art shows an array of compounds. Some cements, however, irritate the pulp and are unsuitable for applications where the cement must come in contact with exposed pulp. Guide to Dental Materials and Devices, 7th Ed. (ADA 1974) p. 49. One solution to this problem is a cement made of materials similar in composition to tooth and bone mineral, since this would not irritate the living tissue.
The use of β--Ca3 (PO4)2 was suggested for pulp capping in Driskell et al, "Development of Ceramic and Ceramic Composite Devices for Maxillofacial Application", J. Biomed. Mat. Res. 6: 345-361 (1972); and the use of Ca4 (PO4)2 O was suggested by the inventors in IADR Abstract. No. 120, J. Dent. Res. 54: 74 (1975) as a possible pulp capping agent. As described in the latter, Ca4 (PO4)2 O hydrolyzes to hydroxyapatite. Therefore, use of a calcium phosphate dental cement should provide a non-irritating cement capable of setting to a hard consistency and, when desired, remineralizing the dental tissue it contacts. Such a cement would be of great benefit, for example, as a root canal or root surface cement.
Single calcium phosphate cements are incapable of setting to a hard consistency, however, and would suffer from the same drawbacks described above for single calcium phosphate remineralizers. They cannot maintain a relatively constant pH and do not have sufficient remineralization capacity. Through U.S. Pat. No. 3,913,229 (Driskell et al) discloses putty-like pastes containing α--Ca3 (PO4)2, β--Ca3 (PO4)2, CaHPO4 and mixtures thereof as pulp capping, root canal, and tooth replanting materials, it is believed that none of these pastes harden into cements. Furthermore, no remineralization properties are disclosed and it is believed that none of these pastes are capable of any substantial remineralization. Thus, there is a need for a dental cement that is non-irritating, yet has good remineralizing capacity coupled with a stable pH.
SUMMARY OF INVENTION
The potential for application of dental remineralization is vast. Approximately 5×108 cavities are filled each year. If these half billion caries lesions were remineralized rather than being filled as cavities, the general dental health would be increased substantially, since remineralization results in a whole tooth. The present invention seeks to provide remineralization compositions and methods that can be practically applied under a dentist's care and thereby replace the need for filling of cavities.
Briefly, the present invention relates to compositions for remineralizing caries lesions. The invention concerns a combination of Ca4 (PO4)2 O (tetracalcium phosphate) and at least one other sparingly soluble calcium phosphate solid in equilibrium or quasi equilibrium with a dilute aqueous solution such that both calcium phosphates are present in excess and form a slurry. The other calcium phosphates that may be used are CaHPO4.2H2 O (dicalcium phosphate dihydrate or brushite), CaHPO4 (monetite), Ca8 H2 (PO4)6.5H2 O (octacalcium phosphate), α--Ca3 (PO4)2, β--Ca3 (PO4)2 (tricalcium phosphates), and tricalcium phosphates modified by the addition of protons or up to approximately 10% magnesium by weight (whitlockite). All combinations of these calcium phosphates can precipitate hydroxyapatite according to the present invention. To do so, however, the two calcium phosphates must be in near equilibrium with the same saturated solution; furthermore, the saturated solution must be supersaturated with respect to hydroxyapatite. If these conditions are met, the above combinations of calcium phosphates will react to form hydroxyapatite. Since the two calcium phosphates are present in excess, the solution will remain supersaturated with respect to hydroxyapatite and will continue to precipitate this basic constituent of tooth and bone.
The advantages of a combination of calcium phosphates according to the present invention as compared with solutions or slurries of a single calcium phosphate are many. Most importantly, the inventive combination of calcium phosphates in a slurry will remain supersaturated with respect to hydroxyapatite for a significant period of time. For example, a combination of tetracalcium phosphate and brushite can remain active as a remineralizer for as long as a week. Thus, a single application of this inventive slurry to a caries lesion would suffice for complete remineralization of the afflicted area. This obviates the need for repeated and lengthy exposures required by previously proposed remineralization systems.
Another significant advantage of the present invention is that the combination of sparingly soluble calcium phosphates stabilizes the pH of the system near the point of equilibrium. This prevents wide swings in pH that might injure the dental enamel or other tissue. A stable pH also permits hydroxyapatite to continue precipitating, since hydroxyapatite will not precipitate at a low pH. Furthermore, the pH of the singular point may be altered by the addition of calcium or phosphate containing compounds to the slurry. This allows the dentist to select the most beneficial pH for remineralization.
Another advantage of the present invention is that the rate of mineralization may be adjusted to the needs of the particular lesion. The addition of simple fluoride compounds will increase the rate of mineralization. Conversely, high molecular weight crystal growth inhibitors may be added to slow mineralization. These latter compounds facilitate the remineralization of the subsurface of a caries lesion by inhibiting the remineralization of the outside surface of the tooth. This allows the hydroxyapatite ions to diffuse into the lesion's subsurface and completely remineralize the cavity.
Thus, the present invention provides compositions for the remineralization of caries lesions that are practical for clinical use due to their large remineralization capacities and stable pH's. The rate and depth of remineralization may be selected by the dentist, thereby giving substantial flexibility to the remineralization process.
The present invention also concerns compounds useful as dental cements. The same combinations of calcium phosphates described above may be combined in a paste, rather than a slurry, and allowed to harden. The resulting cements are similar in composition to tooth and bone material and, therefore, are fully compatible with dental tissue. Though the cements of the present invention may be used in any application for which conventional dental cements are suitable, the cements of the present invention are particularly helpful where contact with living tissue is required. In addition, these cements provide the unique combination of remineralizing properties and hardening characteristics that would be especially desirable for a root canal or root surface cement because they are compatible with, protect and remineralize the sensitive surfaces of exposed roots.
Further objects and features of the invention will become apparent from the following description of the preferred embodiments and claims.
BRIEF DESCRIPTION OF THE DRAWING
FIG. 1 is a plot of the solubility isotherms of Ca4 (PO4)2 O; CaHPO4.2H2 O; CaHPO4 ; Ca8 H2 (PO4)6.5H2 O; β--Ca3 (PO4)2 ; and Ca5 (PO4)3 OH at 25° C. in the ternary system of Ca(OH)2 ; H3 PO4 ; and H2 O.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The sparingly soluble calcium phosphates that are relatively stable at ambient temperatures and are, therefore, available for use in the inventive remineralizing slurries and cements include CaHPO4.2H2 O; CaHPO4 ; Ca8 H2 (PO4)6.5H2 O; α--Ca3 (PO4)2 ; β--Ca3 (PO4)2 ; tricalcium phosphates modified by protons or up to approximately 10% magnesium by weight; and Ca4 (PO4)2 O. Each of these calcium phosphates has a characteristic solubility behavior that may be represented by a plot of the total concentration of calcium ions at the point of saturation verus the pH of the solution at a constant temperature. (A plot of the total concentration of phosphate ions versus pH would be equivalent for the purposes of the present invention because the concentrations of phosphate and calcium ions in solution are linked.) The resulting curve is called an isotherm.
When the isotherms for various calcium phosphates are plotted on the same axes, their solubility behavior relative to each other may be determined. Specifically, a calcium phosphate whose isotherm lies above the isotherm of another calcium phosphate at a given pH is metastable with respect to the latter. The point where the isotherms of two calcium phosphates intersect is known as a singular point. In a solution that is saturated with respect to the two calcium phosphates, both calcium phosphates will be in equilibrium with the saturated solution at the singular point. This means that neither calcium phosphate will precipitate out of solution, but another calcium phosphate whose isotherm lies below the singular point can precipitate. The present invention relates to combinations of calcium phosphates that form signular point solutions that precipitate hydroxyapatite.
FIG. 1 is a plot of the solubility isotherms for six calcium phosphates in the ternary system comprising Ca(OH)2, H3 PO4 and H2 O at 25° C. The y-axis of FIG. 1 represents the total concentration of calcium ions in solution in moles per liter, while the x-axis represents pH. The isotherms for CaHPO4.2H2 O, CaHPO4, β--Ca3 (PO4)2 and Ca5 (PO4)3 OH are based, respectively, on the following articles: Gregory et al, "Solubility of CaHPO4.2H2 O in the System Ca(OH)2 --H3 PO4 --H2 O at 5°, 15°, 25° and 37.5° C.", J. Res. Nat. Bur. Stand. 74A: 461-475 (1970); McDowell et al, "Solubility Study of Calcium Hydrogen Phosphate. Ion Pair Formation", Inorg. Chem. 10: 1638-1643 (1971); Gregory et al., "Solubility of β--Ca3 (PO4)2 in the System Ca(OH)2 --H3 PO4 --H2 O at 5°, 15°, 25° and 37° C.", J. Res. Nat. Bur. Stand. 78A; 667-674 (1974); and McDowell et al, "Solubility of Ca5 (PO4)3 OH in the System Ca(OH)2 --H3 PO4 --H2 O at 5°, 15°, 25° and 37.5° C.", J. Res. Nat. Bur. Stand. 81A: 273-281 (1977). The isotherm for Ca8 H2 (PO4)6.5H2 O is based on the solubility product disclosed on Moreno et al, "Stability of Dicalcium Phosphate Dihydrate in Aqueous Solutions and Solubility of Octacalcium Phosphate", Soil Sci. Soc. Am. Proc. 21: 99-102 (1960), while the isotherm of Ca4 (PO4)2 O is based on the approximate value of the solubility product calculated by the inventors.
As can be seen from FIG. 1, not all combinations of calcium phosphates have singular points. For example, the isotherms of CaHPO4.2H2 O and CaHPO4 never cross at ambient temperature. Therefore, this pair of calcium phosphates cannot be in equilibrium with the same saturated solution at their singular point and do not fall within the scope of the present invention.
Three additional considerations limit the choice of calcium phosphates for the present invention. First, the inventive combinations of calcium phosphates must contain Ca4 (PO4)2 O in order to possess the desired remineralization properties. Second, the singular point of the two calcium phosphates must lie above the isotherm for hydroxyapatite. This insures that a solution that is saturated with respect to the two calcium phosphates at their singular point will also be supersaturated with respect to hydroxyapatite. Thus, hydroxyapatite can precipitate out of the solution and be available for remineralization. Third, the singular point for the pair of calcium phosphates should preferably not lie too far above the isotherm for CaHPO4.2H2 O, since the singular point of such a combination might be too unstable for use as a remineralizer or cement. Therefore, although β--Ca3 (PO4)2 and Ca8 H2 (PO4)6.5H2 O have intersecting isotherms, their singular point lies far above the isotherm for CaHPO4.2H2 O and is unsuitable.
The circles in FIG. 1 define singular point compositions for the various pairs of solids in solution. As can be seen from FIG. 1, the following combinations of calcium phosphates are definitely available as remineralizers and cements according to the present invention: CaHPO4.2H2 O with Ca4 (PO4); CaHPO4 with Ca4 (PO4)2 O; Ca4 (PO4)2 O with Ca8 H2 (PO4)6.5H2 O; and Ca4 (PO4)2 O with β--Ca3 (PO4)2. Additionally, there is potentially another singular point composition containing α--Ca3 (PO4)2 and Ca4 (PO4)2 O. Likewise, the isotherms of the modified tricalcium phosphates may define additional inventive compositions.
The reason that a singular point composition has such desirable properties as a remineralizer and cement is that it resists changes in the pH or composition of the solution by driving itself back to the singular point whenever the composition or pH changes. For example, if two calcium phosphates that possess a singulr point were present in excess in a solution that was more acidic than the pH of the singular point, the more basic phosphate would dissolve and cause the more acidic phosphate to precipitate. This process would continue until the pH and the composition were forced back to the singular point, where the two calcium phosphates present in excess would both be in equilibrium with the solution and neither would precipitate out of solution. The reverse process would occur if the composition started at a point more basic than the singular point pH.
When only two salts are present in the solution, the composition of the solution cannot rise above the isotherm of the more soluble salt or fall below the isotherm of the less soluble salt. Furthermore, the solution will only be in equilibrium at the singular point. However, the precipitation of a third salt, such as hydroxyapatite, may drive the composition in the direction of the third salt's isotherm. The degree of deviation depends upon the relative rates of dissolution and precipitation of the three salts.
For the purposes of remineralization, it would be undesirable if the solution's composition deviated too close to the isotherm of hydroxyapatite since this would lower the rate of precipitation of hydroxyapatite. However, since the two calcium phosphates are present in excess, the relative rate of precipitation for hydroxyapatite is likely to be small when compared to the dissolution and precipitation rates of the other two calcium phosphates, and the composition will remain in the vicinity of the singular point. Thus, a slurry containing excessive amounts of two calcium phosphates having a singular point can remain approximately at the pH and composition of the singular point despite the constant production and precipitation of hydroxyapatite. It is this feature of the present invention that permits a remineralizing slurry or paste to remain active as a remineralizer for a substantial period of time without great shifts in pH or composition.
The combinations of calcium phosphates listed above all react to form hydroxyapatite. Since Ca4 (PO4)2 O is the most basic calcium phosphate of the present invention, any of the remaining calcium phosphates that are more acidic than hydroxyapatite can react directly with tetracalcium phosphate to form hydroxyapatite. For example,
Ca.sub.4 (PO.sub.4).sub.2 O+CaHPO.sub.4.2H.sub.2 O=Ca.sub.5 (PO.sub.4).sub.3 OH+2H.sub.2 O;
Ca.sub.4 (PO.sub.4).sub.2 O+CaHPO.sub.4 =Ca.sub.5 (PO.sub.4).sub.3 OH;
3Ca.sub.4 (PO.sub.4).sub.2 O+Ca.sub.8 H.sub.2 (PO.sub.4).sub.6.5H.sub.2 O=4Ca.sub.5 (PO.sub.4).sub.3 OH+4H.sub.2 O;
and
Ca.sub.4 (PO.sub.4).sub.2 O+2Ca.sub.3 (PO.sub.4).sub.2 [α,β, or modified]+H.sub.2 O=2Ca.sub.5 (PO.sub.4).sub.3 OH.
Unexpectedly, it has been discovered by the inventors that Ca4 (PO4)2 O is a necessary ingredient for the inventive compositions to be effective remineralizing agents.
The reaction approximated by 5Ca8 H2 (PO4)6.5H2 O=8Ca5 (PO4)3 OH+6H3 PO4 +17H2 O, is of particular interest for remineralization, because under many conditions the rate of formation of octacalcium phosphate appears to be much greater than the rate of formation of hydroxyapatite. Since octacalcium phosphate can hydrolyze in situ to hydroxyapatite, the formation of Ca8 H2 (PO4)6.5H2 O followed by hydrolysis to hydroxyapatite may be a particularly efficacious method for the production of hydroxyapatite in remineralizing solutions. The only known combinations of calcium phosphates that definitely can form octacalcium phosphate as a precursor to hydroxyapatite are Ca4 (PO4)2 O with CaHPO4.2H2 O and CaHPO4 since their singular points both lie above the isotherm for Ca8 H2 (PO4)6.5H2 O.
The inventive combinations may also be used as densitizing agents due to their remineralization properties. Since clogging of the dental tubules reduces the pain sensitivity of the dental tissue, the remineralization promoted by the inventive compositions also tends to desensitize the remineralized tissue.
The pH range of the inventive system may be predetermined by choosing a pair of calcium phosphates with an appropriate singular point pH. For example, if a pH around 7.5 is desired, one could use the combination of CaHPO4.2H2 O and Ca4 (PO4)2 O. The pH of any slurry or paste may be further altered by the addition of up to approximately 10% by weight of simple calcium or phosphate containing compounds. These compounds change the pH of the singular point by altering the Ca/P ratio of the solution. Since the chemical potentials of Ca(OH)2 and H3 PO4 have been shown to be invariant in the presence of additional components at a given singular point [see Brown, "Solubilities of Phosphates and Other Sparingly Soluble Compounds", from Griffith et al, Environmental Phosphorous Handbook (John Wiley & Sons, New York 1973)], the ratio (Ca2+)/(H+)2 is constant at a given singular point, where the parentheses denote ion activities. Thus, the addition of an acidic compound, such as HCl, CaCl2, or Ca(C2 H3 O2)2, will increase the ionic activity of Ca2+, increase the Ca/P ratio of the singular point and cause the singular point to move to a lower pH. Similar considerations hold for the addition of basic compounds. Examples of suitable base and phosphate containing compounds are NaH2 PO4 and (NH4)H2 PO4.
The rate of remineralization may also be adjusted. The addition of simple or complex fluoride compounds such that the fluoride content of the slurry or paste is up to approximately 3.8% by weight will increase the rate of precipitation of hydroxyapatite and decrease solubility, thereby providing a control on the body's ability to resorb the material. Examples of possible fluoride additives are CaF2, SnF2, NaF, Na2 SiF6, and Na2 PO3 F. Though rapid mineralization is beneficial under some circumstances, it may cause the remineralization of the outside surface of an incipient caries lesion and prevent the remineralization of the subsurface region of the lesion. A moderately slow remineralization rate would allow all parts of the lesion to be healed. The particular calcium phosphates used will affect the rate of remineralization. In addition, particle size is a factor since as particle size increases, the rate of mineralization decreases. Generally the particle size for remineralization slurries should be greater than 5 um. Thus, to remineralize a deep lesion, a slow remineralizing slurry could be applied to the tooth by means of a bite block sponge, periodontal pack, cement or rigid gel.
It is also possible to facilitate internal remineralization by etching the surface of the tooth such that the remineralizing slurry can contact more of the lesion's surface at once. Another solution to the problem of incomplete internal remineralization is the application of high molecular weight crystal growth poisons or inhibitors onto the tooth surrface. Examples of such growth inhibitors are proteoglycans, glycoproteins, polylysine, and protamine. Concentrations of up to approximately 5% by weight may be added to the remineralizing slurry. These inhibitors prevent the growth of hydroxyapatite crystals at the surface of the tooth but do not tend to diffuse into the interior of the tooth. Accordingly, they inhibit the remineralization of the caries lesion's surface and prevent the blockage of the channels necessary for the diffusion of calcium and phosphate ions into the subsurface lesion.
All of the combinations of calcium phosphates described above may be used as dental cements. The two main differences between the inventive remineralizers and the inventive cements are particle size and solid-to-liquid ratio. For use as cements, the selected calcium phosphates should be ground to a finer particle size, preferably less than 5 μm. Additionally, calcium phosphate particles are combined with much less solution so that a paste is formed rather than a slurry. The paste then hardens to a bone-like consistency.
Porous cements that are especially useful as bone implants or protheses may be prepared by combining the calcium phosphates with a highly water soluble material, such as granular sugar, and subjecting the mixture to pressure sufficient to form a compact mass. The water necessary for the inventive reaction is usually contained in the calcium phosphates themselves. However, a small amount of water may be added to the mixture before pressure is applied in order to facilitate the setting of the cement. The resulting mass is then placed into hot water such that the highly water soluble material is removed. A porous cement remains that is readily permeated by organic bone tissue.
In order to improve the flow properties of the inventive dental cement pastes, it is desirable to incorporate glycerin, ethanol, glycol or some other nontoxic organic solvent into the paste. Since the cement mixture ingredients are inert to glycerin, a nonaqueous paste containing Ca4 (PO4)2 O and another calcium phosphate in glycerin will not harden or set. Thus, such a water free glycerin-based paste can be stably preserved in a moisture-free sealed tube for several months. However, when the glycerin paste is exposed to humid air or to water, setting occurs quite rapidly. Additionally, the glycerin serves as a vehicle for the inventive combinations and produces desirable flow properties for the paste such that the paste may be injected or delivered through a fine orifice or tubing. Thus glycerin aids such operations as the delivery of the inventive pastes into root canals using a one millimeter syringe fitted with an 18 gauge needle. The glycerin eventually leaches out of the set or hardened cement.
The cements of the present invention may be used in place of any of the cements known in the prior art as: (i) cavity bases and liners to protect the pulp; (ii) materials for capping exposed pulps; (iii) materials to replace or promote regeneration of bone mineral lost due to periodontal disease; (iv) direct filling materials that have physical properties similar to enamel and are adhesive to enamel and dentin; (v) a cement to build up alveolar ridges in edentulous patients; (vi) an endodontic filling material for root canals; (vii) a material to cement retention pins; (viii) a material for filling sockets after a tooth extraction; (ix) a replacement of bone that has been removed surgically or lost due to trauma; (x) a cement for implanting or replanting teeth; (xi) a luting cement in densitry and orthopedic surgury; (xii) an investment mold material; (xiii) a material which will promote bone mineral growth in its vicinity; (xiv) a remineralizing polish for use in place of pumice; and (xv) a root cement for remineralizing and densitizing of exposed root surfaces. Since the inventive cements are fully compatible with living tissue, they are especially advantageous where contact with dental tissue is necessary. in addition, the cements possess remineralization capabilities. Thus, the discussion above with respect to the use of the inventive compositions as remineralizers is fully applicable to their use as cements.
The strength and hardness of the present cements can be controlled by the particle size of the calcium phosphates, the presence of hydroxyapatite or Ca5 (PO4)3 F (fluorapatite) as seed or matrix crystals, and by the use of crystal habit modifiers. These last compounds promote the growth of more needle-like apatitic crystals in the cement. It is believed that a particle size of 1 μm would result in a very strong cement.
The setting time of the present cements may be reduced by adding a sizable amount of hydroxyapatite or fluorapatite seed crystals to the paste as these compounds facilitate crystal formation. This may also increase the hardness of the cement and minimize shrinkage or expansion during set. The addition of Ca5 (PO4)2 SiO4 or silicocarnotite may also improve the setting properties of the cements. Of course, it may be desirable to have some setting expansion when the paste is used in a cavity preparation in order to promote adhesion to the cavity wall. Such expansion may be achieved by the addition of β--Ca3 (PO4)2 or up to 1% by weight of crystal habit modifiers, such as Mg2+, Sr2+, citrate, phosphates, carbonate, polyphosphates, sucrose phosphate and phosphocitrate. These modifiers adsorb onto the specific sites of the crystal surfaces during growth, thereby affecting the morphology of the crystals. Additionally, appropriate combinations of varying or "gap-graded" particle sizes would promote setting expansion.
It has also been determined that when fluoride compounds are added to the liquid or solid phase, the setting time may be reduced further for the same seed crystal content.
EXAMPLE 1
Ca4 (PO4)2 O and another calcium phosphate having a singular point with Ca4 (PO4)2 O at an appropriate pH are selected. Their singular point should not lie too far above the isotherm for CaHPO4.2H2 O and must lie above the isotherm for hydroxyapatite. The calcium phosphates selected may be prepared by the methods described in McDowell et al, "Solubility Study of Calcium Hydrogen Phosphate. Ion-Pair Formation", Inorg. Chem. 10: 1638-1643 (1971); Gregory et al, "Solubility of β--Ca3 (PO4)2 in the System Ca(OH)2 --H3 PO4 --H2 O at 5°, 15°, 25° and 37° C.", J. Res. Nat. Bur. Stand. 78A: 667-674 (1974); Moreno et al, "Stability of Dicalcium Phosphate Dihydrate in Aqueous Solutions and Solubility of Octacalcium Phosphate", Soil Sci. Soc. Am. Proc. 21: 99-102 (1960); Brown et al, "Crystallography of Tetracalcium Phosphate", J. Res. Nat. Bur. Stands. 69A: 547-551 (1965); and Patel et al, "Solubility of CaHPO4.2H2 O in the Quaternary System Ca(OH)2 --H3 PO4 --NaCl--H2 O at 25° C.", J. Rest. Nat. Bur. Stands. 78A: 675-681 (1974). The calcium phosphates may be in crystalline, cryptocrystalline, finely divided, or amorphous form.
Each of the selected, solid calcium phosphates is then ground to the desired particle size. Generally for remineralization slurries, the particle size should be greater than 5 μm, since this size prolongs the remineralization potential of the slurry by slowing the remineralization rate. Larger particle size both slows the reaction rate and retards the setting or hardening of the slurry.
The ground calcium phosphates are then mixed in excess in a dilute aqueous solution that is either slightly acidic or slightly basic to form a slurry. Alternatively, gelling agents such as carboxylmethyl cellulose may be added to the slurry such that an aqueous gel is formed. Examples of appropriate acidic solutions are water and H3 PO4 or HCl, while examples of appropriate basic solutions are water and Ca(OH)2 or KOH. The slurry may be applied to the affected area by means of a bite block sponge, periodontal pack, cement, or rigid gel. Also the slurry may be applied by burnishing, spatulation or packing and covering by various mechanical means. Additionally, the slurry may be allowed to harden and thereby act as its own cement for holding the remineralizer against the afflicted area.
Alternatively, the above remineralizing combinations may be incorporated into chewing gum formulations by blending the solid and liquid phases with a chewing gum base in the manner practiced in the industry. Similarly, the solid and liquid phases may be combined with the common ingredients of toothpaste. In these cases the particle size of the calcium phosphates should be such as to avoid grittiness. Another alternative is to apply the above remineralizing combinations as a dry powder. The remineralizing properties of the powder are then activated by the addition of an appropriate aqueous solvent, such as water or saliva.
In addition, four groups of compounds may be added to the liquid phase of the remineralization slurry. Alternatively, these compounds can be added to the dry powder remineralizing combinations. First, fluoride compounds, such as CaF2, SnF2, NaF, Na2 SiF6, or Na2 PO3 F, may be added to increase the rate of mineralization. Second, calcium and phosphate containing compounds, such as CaCl2, Ca(C2 H3 O2)2, NaH2 PO4, or (NH4)H2 PO4, may be added to modify the Ca/P ratio and pH of the solution's singular point. Third, high molecular weight crystal growth inhibitors may be added to facilitate the complete remineralization of the subsurface caries lesions. Fourth, a gelling agent may be added.
EXAMPLE 2
Ca4 (PO4)2 O and CaHPO4.2H2 O are ground to an approximate mean particle size of 40 μm. Two grams of an equimolar mixture of the two solids is combined with 20 ml of a 5 mM H3 PO4 solution and mixed to form a slurry. The slurry is then placed on a caries lesion by means of a bite block sponge. This slurry will maintain a pH in the vicinity of 7.4 and precipitate hydroxyapatite for almost one week.
EXAMPLE 3
To form a dental cement, Ca4 (PO4)2 O and at least one other calcium phosphate selected from the group consisting of CaHPO4.2H2 O, CaHPO4, Ca8 H2 (PO4)6.5H2 O, α--Ca3 (PO4)2, β--Ca3 (PO4)2, and modified Ca3 (PO4)2 are ground to a uniform particle size of less than 5 μm so that the setting time will be reasonable. If some setting expansion is required, "gap-graded" particle sizes may be used. The calcium phosphates are then combined with the dilute aqueous solutions of Example 1 to form a paste. This paste is then applied by an appropriate means to the affected area. For example, if the cement is to be used as an endodontic filling material, the paste may be applied by injection or packed with a plugger. Alternatively, the calcium phosphates are combined with a nonaqueous medium such as glycerin, ethanol or glycol to form a paste. These nonaqueous pastes will harden upon exposure to the dilute aqueous solutions of Example 1 or humid air. Alternatively, the combined calcium phosphates may be applied as a dry powder that will form a hardenable paste upon contact with an appropriate aqueous solvent such as water or saliva.
To modify the remineralization properties of the cement, the additives described in Example 1 may be added to the liquid or solid phase. In addition, crystal habit modifiers may be added to induce more needle-like growth of apatitic crystals. The setting time for a given cement may be reduced by adding hydroxyapatite or fluorapatite seed crystals. The inclusion of fluoride compounds will further reduce the setting time. Silicocarnotite may improve the setting properties of the cement.
Setting expansion and shrinkage may be reduced by adding a sizeable amount of hydroxyapatite to the paste. Conversely, some setting expansion may be encouraged by the addition of β--Ca3 (PO4)2 or crystal habit modifiers.
EXAMPLE 4
Specimens 1-5 shown in Table I were prepared as follows. The two calcium phosphates and hydroxyapatite seed were all ground to a mean particle size of 5 μm. One gram of a mixture containing equimolar amounts of the two calcium phosphates and the appropriate weight percent of Ca5 (PO4)3 OH was mixed with 0.5 ml of the appropriate H2 PO4 solution. All of the specimens were stirred into pastes, allowed to harden, and were soaked in H2 O at 37° C. for twenty-four hours. The compressive strengths in pounds per square inch were then determined as shown in Table I.
EXAMPLE 5
Specimens 6-9 shown in Table II were prepared by grinding Ca4 (PO4)2 O, CaHPO4.2H2 O, and Ca5 (PO4)3 OH to a mean particle size of 5 μm. One gram of a mixture containing equimolar amounts of Ca4 (PO4)2 O and CaHPO4.2H2 O and the appropriate weight percent of Ca5 (PO4)3 OH was mixed with 0.5 ml of 20 mM H3 PO4 to form a paste. This paste was then allowed to harden. The setting times as a function of apatite seed content are shown in Table II.
EXAMPLE 6
To form a porous cement of increased strength, Ca4 (PO4)2 O and CaHPO4.2H2 O are ground to a mean particle size of 5 μm. Two grams of a mixture containing equimolar amounts of the two calcium phosphates and 0.5 gram of granular sugar (or another highly water soluble material) are mixed and placed in a mold. Usually addition of water to the mixture is not needed but a small amount may be added in some instances to facilitate the setting reaction. Up to 80,000 pounds per square inch of pressure is applied to the cement mixture using a press for two minutes. The specimen, which is made into a compact mass by the process, is placed in boiling water to extract the water soluble granules and to complete the setting process. The resulting porous materials can be used as protheses which can be invaded more readily by organic bone tissue.
It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit or scope of the invention.
                                  TABLE 1                                 
__________________________________________________________________________
COMPRESSIVE STRENGTHS OF EXPERIMENTAL CEMENTS                             
                    Ca.sub.5 (PO.sub.4).sub.3 OH, Wt. %                   
                                       Compressive Strength               
Specimen                                                                  
     Calcium Phosphates                                                   
                    Seed Content                                          
                               Solution                                   
                                       (PSI).sup.1                        
__________________________________________________________________________
1    CaHPO.sub.4.2H.sub.2 O + Ca.sub.4 (PO.sub.42)O                       
                    0           5 mM H.sub.3 PO.sub.4                     
                                       4390 ± 860(3)                   
2    CaHPO.sub.4.2H.sub.2 O + Ca.sub.4 (PO.sub.4).sub.2 O                 
                    0          20 mM H.sub.3 PO.sub.4                     
                                       4560 ± 520(3)                   
3    CaHPO.sub.4 + Ca.sub.4 (PO.sub.4).sub.2 O                            
                    0          20 mM H.sub.3 PO.sub.4                     
                                       4960 ± 650(3)                   
4    CaHPO.sub.4 + Ca.sub.4 (PO.sub.4).sub.2 O                            
                    2.7        20 mM H.sub.3 PO.sub.4                     
                                       4280 ± 940(2)                   
5    CaHPO.sub.4 + Ca.sub.4 (PO.sub.4).sub.2 O                            
                    9.6        20 mM H.sub.3 PO.sub.4                     
                                        4578 ± 1010(2)                 
__________________________________________________________________________
 .sup.1 Compressive strengths are shown as mean value ± standard       
 deviation. The number of samples is shown in parenthesis                 
              TABLE II                                                    
______________________________________                                    
SETTING TIME AS A FUNCTION OF                                             
HYDROXYAPATITIC SEED CONTENT                                              
FOR EXPERIMENTAL CEMENTS                                                  
                            Setting time.sup.1                            
Specimen Ca.sub.5 (PO.sub.4).sub.3 OH Content, Wt. %                      
                            Min.                                          
______________________________________                                    
6         0                 22                                            
7        24                 11                                            
8        34                  9                                            
9        43                 8                                             
______________________________________                                    
 .sup.1 The setting times were measured according to American Dental      
 Association Specification No. 9                                          

Claims (30)

We hereby claim as our invention:
1. A .[.dental restorative.]. slurry .[.comprising.]. .Iadd.consisting essentially of .Iaddend.an aqueous mixture of Ca4 (PO4)2 O and at least one other calcium phosphate selected from the group consisting of CaHPO4.2H2 O.[.,.]. .Iadd.and .Iaddend.CaHPO4, .[.Ca8 H2 (PO4)6.5H2 O, α--Ca3 (PO4)2, β--Ca3 (PO4)2, and modified Ca3 (PO4)2,.]. both calcium phosphates being present in the slurry in excess such that hydroxyapatite is substantially continuously precipitated from the slurry .Iadd.at an ambient temperature.Iaddend..
2. The slurry of claim 1 wherein the other calcium phosphate is CaHPO4.2H2 O.
3. The slurry of claim 1 wherein the other calcium phosphate is CaHPO4. .[.4. The slurry of claim 1 wherein the other calcium phosphate is Ca8 H2 (PO4)6.5H2 O..]. .[.5. The slurry of claim 1 wherein the other calcium phosphate is β--Ca3
(PO4)2..]. 6. The slurry of claim 1 wherein at least one of the calcium phosphates is in crystalline, cryptocrystalline or amorphous form.
. The slurry of claim 1 further .[.comprising.]. .Iadd.including .Iaddend.up to approximately 10% by weight of additional calcium or phosphate containing compounds .Iadd.in an amount sufficient to alter the
pH of the slurry.Iaddend.. 8. The slurry of claim 7 wherein the additional calcium containing compounds .[.comprise.]. .Iadd.are selected from the group consisting of .Iaddend.CaCl2 .[.or.]. .Iadd.and
.Iaddend.Ca(C2 H3 O2)2. 9. The slurry of claim 7 wherein the additional phosphate containing compounds .[.comprise.]. .Iadd.are selected from the group consisting of .Iaddend.NaH2
PO4 .[.or.]. .Iadd.and .Iaddend.(NH4)H2 PO4. 10. The slurry of claim 1 further .[.comprising.]. .Iadd.including .Iaddend.fluoride containing compounds such that the fluoride content of the slurry is up to approximately 3.8% by weight .Iadd.in an amount sufficient to increase the rate of precipitation of hydroxyapatite from
the slurry.Iaddend.. 11. The slurry of claim 10 wherein the fluoride containing compounds .[.comprise.]. .Iadd.are selected from the group consisting of .Iaddend.CaF2, SnF2, NaF, Na2 SiF6
.[.or.]. .Iadd.and .Iaddend.NaPO3 F. 12. The slurry of claim 1 further .[.comprising.]. .Iadd.including .Iaddend.a gelling agent .Iadd.in
an amount sufficient to form an aqueous gel.Iaddend.. 13. A .[.dental restorative.]. paste .[.comprising.]. .Iadd.consisting essentially of .Iaddend.a nonaqueous mixture of a nontoxic organic solvent, Ca4 (PO4)2 O and at least one other calcium phosphate selected from the group consisting of CaHPO4.2H2 O.[.,.]. .Iadd.and .Iaddend.CaHPO4, .[.Ca8 H2 (PO4)6.5H2 O, α--Ca3 (PO4)2, β--Ca3 (PO4)2 and modified Ca3 (PO4)2, the paste being capable of hardening.]. .Iadd.which nonaqueous mixture hardens .Iaddend.into a cement upon contact with an aqueous medium .Iadd.at an ambient
temperature.Iaddend.. 14. The paste of claim 13 wherein the other calcium
phosphate is CaHPO4.2H2 O. 15. The paste of claim 13 wherein the other calcium phosphate is CaHPO4. .[.16. The paste of claim 13 wherein the other calcium phosphate is Ca8 H2 (PO4)6.5H2 O..]. .[.17. The paste of claim 13 wherein the
other calcium phosphate is β--Ca3 (PO4)2..]. 18. The paste of claim 13 wherein at least one of the calcium phosphates is in
crystalline, cryptocrystalline or amorphous form. 19. The paste of claim 13 further .[.comprising.]. .Iadd.including .Iaddend.up to approximately 10% by weight of additional calcium or phosphate containing compounds
.Iadd.in an amount sufficient to alter the pH of the paste.Iaddend.. 20. The paste of claim 19 wherein the additional calcium containing compounds .[.comprise.]. .Iadd.are selected from the group consisting of .Iaddend.CaCl2 .[.or.]. .Iadd.and .Iaddend.Ca(C2 H3
O2)2. 21. The paste of claim 19 wherein the additional phosphate containing compounds .[.comprise.]. .Iadd.are selected from the group consisting of .Iaddend.NaH2 PO4 .[.or.]. .Iadd.and
.Iaddend.(NH4)H2 PO4. 22. The paste of claim 13 further .[.comprising.]. .Iadd.including .Iaddend.fluoride containing compounds such that the fluoride content of the .[.slurry.]. .Iadd.paste .Iaddend.is up to approximately 3.8% by weight .Iadd.in an amount sufficient to increase the rate of precipitation of hydroxyapatite from the
paste.Iaddend.. 23. The paste of claim 22 wherein the fluoride containing compounds .[.comprise.]. .Iadd.are selected from the group consisting of .Iaddend.CaF2, SnF2, NaF, Na2 SiF6 .[.or.]. .Iadd.and
.Iaddend.NaPO3 F. 24. The paste of claim 13 further .[.comprising.]. .Iadd.including .Iaddend.a seed crystal compound selected from the group consisting of hydroxyapatite and fluorapatite .Iadd.in an amount
sufficient to reduce the setting time of the cement.Iaddend.. 25. The paste of claim 13 wherein the aqueous medium is humid air or a dilute
aqueous solvent. 26. A .[.dental restorative.]. powder .[.comprising.]. .Iadd.consisting essentially of .Iaddend.a mixture of Ca4 (PO4)2 O and at least one other calcium phosphate selected from the group consisting of CaHPO4.2H2 O.[.,.]. .Iadd.and .Iaddend.CaHPO4, .[.Ca8 H2 (PO4)6.5H2 O, α--Ca3 (PO4)2, β--Ca3 (PO4)2, and modified Ca3 (PO4)2,.]. the powder .[.being capable of.]. forming .[.a.]. slurry .Iadd.of claim 1 .Iaddend.upon contact with an appropriate aqueous solvent.[., the slurry being capable of substantially continuously precipitating hydroxyapatite.]. .Iadd.at an ambient
temperature.Iaddend.. 27. The powder of claim 26 wherein the solvent is
water or saliva. 28. A .[.dental restorative.]. powder .[.comprising.]. .Iadd.consisting essentially of .Iaddend.a mixture of Ca4 (PO4)2 O and at least one other calcium phosphate selected from the group consisting of CaHPO4.2H2 O.[.,.]. .Iadd.and .Iaddend.CaHPO4, .[.Ca8 H2 (PO4)6.5H2 O, α--Ca3 (PO4)2, β--Ca3 (PO4)2, and modified Ca3 (PO4)2,.]. the powder .[.being capable of forming a hardenable.]. .Iadd.hardening into a .Iaddend.cement upon contact with an appropriate aqueous solvent .Iadd.at an ambient
temperature.Iaddend.. 29. The powder of claim 28 wherein the solvent is
water or saliva. .Iadd.30. The slurry of claim 1 additionally including up to approximately 5% by weight of a high molecular weight crystal growth inhibitor selected from the group consisting of proteoglycans, glycoproteins, polylysine and protamine in an amount sufficient to inhibit
the growth of hydroxyapatite crystals. .Iaddend. .Iadd.31. The slurry of claim 1 wherein the slurry is slightly basic. .Iaddend. .Iadd.32. The slurry of claim 1 wherein the slurry is slightly acidic. .Iaddend. .Iadd.33. The slurry of claim 1 wherein the slurry is incorporated into a chewing gum. .Iaddend. .Iadd.34. The slurry of claim 1 where in the slurry
is incorporated into a toothpaste. .Iaddend. .Iadd.35. The paste of claim 24 wherein the seed crystal compound is hydroxyapatite, the hydroxyapatite being present in an amount up to 43% by weight and in an amount sufficient to reduce the setting time of the cement. .Iaddend. .Iadd.36. The paste of claim 13 additionally including up to approximately 5% by weight of a high molecular weight crystal growth inhibitor selected from the group consisting of proteoglycans, glycoproteins, polylysine and protamine in an amount sufficient to inhibit the growth of hydroxyapatite crystals. .Iaddend. .Iadd.37. The paste of claim 13 additionally including β--Ca3 (PO4)2 in an amount sufficient to achieve setting expansion of the cement. .Iaddend. .Iadd.38. The paste of claim 13 additionally including up to 1% by weight of a crystal habit modifier selected from the group consisting of Mg2+, Sr2+, citrate, phosphonates, carbonate, polyphosphates, sucrose phosphate, and phosphocitrate in an amount sufficient to achieve setting expansion of the
cement. .Iaddend. .Iadd.39. The paste of claim 13 additionally including Ca5 (PO4)2 SiO4 or silicocarnotite in an amount sufficient to improve the setting properties of the cement. .Iaddend. .Iadd.40. The paste of claim 13 wherein the nontoxic organic solvent is selected from the group consisting of glycerin, ethanol and glycol. .Iaddend. .Iadd.41. The paste of claim 13 additionally including granular sugar, the sugar being present in an amount up to 20% by weight and in an amount sufficient to form a porous cement upon removal of the sugar by application of hot water to the cement. .Iaddend. .Iadd.42. The powder of claim 28 wherein the other calcium phosphate is CaHPO4.2H2 O. .Iaddend. .Iadd.43. The powder of claim 28 wherein the other calcium phosphate is CaHPO4. .Iaddend. .Iadd.44. The powder of claim 28 wherein at least one of the calcium phosphates is in crystalline, cryptocrystalline or amorphous form. .Iaddend. .Iadd.45. The powder of claim 28 further including up to approximately 10% by weight of additional calcium or phosphate containing compounds in an amount sufficient to alter the pH of the accent. .Iaddend. .Iadd.46. The powder of claim 45 wherein the additional calcium containing compounds are selected from the group consisting of CaCl2 and Ca(C2 H3 O2)2. .Iaddend. .Iadd.47. The powder of claim 45 wherein the additional phosphate containing compounds are selected from the group consisting of NaH2 PO4 and (NH4)H2 PO4. .Iaddend. .Iadd.48. The powder of claim 28 further including fluoride containing compounds such that the fluoride content is up to approximately 3.8% by weight in an amount sufficient to increase the rate of precipitation of hydroxyapatite from the cement. .Iaddend. .Iadd.49. The powder of claim 48 wherein the fluoride containing compounds are selected from the group consisting of CaF2, SnF2, NaF, Na2 SiF6 and NaPO3 F. .Iaddend. .Iadd.50. The powder of claim 28 further including a seed crystal compound selected from the group consisting of hydroxyapatite and fluorapatite in an amount sufficient to reduce the setting time of the cement. .Iaddend. .Iadd.51. The powder of claim 50 wherein the seed crystal compound is hydroxyapatite, the hydroxyapatite being present in an amount up to 43% by weight and in an amount sufficient to reduce the setting time of the
cement. .Iaddend. .Iadd.52. The powder of claim 28 additionally including up to approximately 5% by weight of a high molecular weight crystal growth inhibitor selected from the group consisting of proteoglycans, glycoproteins, polylysine and protamine in an amount sufficient to inhibit the growth of hydroxyapatite crystals. .Iaddend. .Iadd.53. The powder of claim 28 additionally including β-Ca3 (PO4)2 in an amount sufficient to achieve setting expansion of the cement. .Iaddend. .Iadd.54. The powder of claim 13 additionally including up to 1% by weight of a crystal habit modifier selected from the group consisting of Mg2+, Sr2+, citrate, phosphonates, carbonate, polyphosphates, sucrose phosphate, and phosphocitrate in an amount sufficient to achieve setting expansion of the cement. .Iaddend. .Iadd.55. The powder of claim 28 additionally including Ca5 (PO4)2 SiO4 or silicocarnotite in an amount sufficient to improve the setting properties of the cement. .Iaddend. .Iadd.56. The powder of claim 28 additionally including granular sugar, the sugar being present in an amount up to 20% by weight and in an amount sufficient to form a porous cement upon removal of the sugar by application of hot water to the cement. .Iaddend.
US07/163,014 1982-04-29 1988-03-02 Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements Expired - Lifetime USRE33161E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/163,014 USRE33161E (en) 1982-04-29 1988-03-02 Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37315782A 1982-04-29 1982-04-29
US06/539,740 US4518430A (en) 1982-04-29 1983-10-06 Dental resptorative cement pastes
US07/163,014 USRE33161E (en) 1982-04-29 1988-03-02 Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US06/539,740 Continuation-In-Part US4518430A (en) 1982-04-29 1983-10-06 Dental resptorative cement pastes
US06/732,515 Reissue US4612053A (en) 1983-10-06 1985-05-09 Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements

Publications (1)

Publication Number Publication Date
USRE33161E true USRE33161E (en) 1990-02-06

Family

ID=27388821

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/163,014 Expired - Lifetime USRE33161E (en) 1982-04-29 1988-03-02 Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements

Country Status (1)

Country Link
US (1) USRE33161E (en)

Cited By (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068100A (en) * 1989-03-09 1991-11-26 The Procter & Gamble Company Anticalculus compositions
US5128169A (en) * 1990-01-08 1992-07-07 Sumitomo Chemical Company, Limited Method for forming hydroxyapatite coating film
US5145520A (en) * 1989-08-29 1992-09-08 Kyoto University Bioactive cement
US5258044A (en) * 1992-01-30 1993-11-02 Etex Corporation Electrophoretic deposition of calcium phosphate material on implants
FR2693716A1 (en) * 1992-07-20 1994-01-21 Toulouse Inst Nat Polytech Process for obtaining phosphocalcic hydroxyapatite, applications for bone or dental filling, or molding of parts, and products used.
US5336264A (en) * 1988-04-20 1994-08-09 Norian Corporation Situ prepared calcium phosphate composition and method
WO1994020064A1 (en) * 1993-03-12 1994-09-15 American Dental Association Health Foundation Calcium phosphate hydroxyapatite precursor and methods for making and using the same
EP0639366A1 (en) * 1993-08-19 1995-02-22 Kingstar Technology Limited (Uk) Hydroxyapatite cement as bone or tooth replacement
US5401783A (en) * 1992-06-15 1995-03-28 American Dental Association Health Foundation Adhesion-promoting agents incorporating polyvalent cations
US5427768A (en) * 1993-06-23 1995-06-27 American Dental Association Health Foundation Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
US5437857A (en) * 1989-05-24 1995-08-01 American Dental Association Health Foundation Methods and compositions for mineralizing and fluoridating calcified tissues
US5460803A (en) * 1989-05-24 1995-10-24 American Dental Association Health Foundation Methods and compositions for mineralizing and fluoridating calcified tissues
US5476647A (en) * 1993-09-13 1995-12-19 American Dental Association Health Foundation Complex calcium and fluoride containing mouth rinses, dentifrices, and chewable tablets
WO1996006041A1 (en) * 1994-08-23 1996-02-29 Norian Corporation Storage stable calcium phosphate cements
US5525148A (en) * 1993-09-24 1996-06-11 American Dental Association Health Foundation Self-setting calcium phosphate cements and methods for preparing and using them
US5534244A (en) * 1989-05-24 1996-07-09 Tung; Ming S. Methods and compositions for mineralizing and/or fluoridating calcified tissues with amorphous strontium compounds
US5550172A (en) * 1995-02-07 1996-08-27 Ethicon, Inc. Utilization of biocompatible adhesive/sealant materials for securing surgical devices
WO1996025914A1 (en) * 1995-02-24 1996-08-29 American Dental Association Health Foundation Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
US5650176A (en) * 1995-05-19 1997-07-22 Etex Corporation Synthesis of reactive amorphous calcium phosphates
US5782971A (en) * 1991-06-28 1998-07-21 Norian Corporation Calcium phosphate cements comprising amorophous calcium phosphate
US5858333A (en) * 1998-08-07 1999-01-12 Enamelon, Inc. Two-part oral products and methods of using same to remineralize teeth
US5900254A (en) 1988-04-20 1999-05-04 Norian Corporation Carbonated hydroxyapatite compositions and uses
US5980625A (en) 1997-03-13 1999-11-09 Ngk Spark Plug Co., Ltd. Calcium phosphate composition and a setting solution therefor
US6002065A (en) 1988-04-20 1999-12-14 Norian Corporation Kits for preparing calcium phosphate minerals
US6005162A (en) 1988-04-20 1999-12-21 Norian Corporation Methods of repairing bone
US6027742A (en) 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US6051061A (en) 1998-03-23 2000-04-18 Ngk Spark Plug Co., Ltd. Calcium phosphate cements and calcium phosphate cement compositions
US6117456A (en) 1995-05-19 2000-09-12 Etex Corporation Methods and products related to the physical conversion of reactive amorphous calcium phosphate
US6139578A (en) 1995-05-19 2000-10-31 Etex Corporation Preparation of cell seeded ceramic compositions
US6287341B1 (en) 1995-05-19 2001-09-11 Etex Corporation Orthopedic and dental ceramic implants
US6312467B1 (en) 1995-07-18 2001-11-06 Iowa State University Research Foundation, Inc. Method of restructuring bone
US6364909B1 (en) 1995-07-18 2002-04-02 Iowa State University Research Foundation, Inc. Method of restructuring bone
WO2002030381A1 (en) * 2000-10-13 2002-04-18 Block Drug Company, Inc. Anhydrous dentifrice formulations for the delivery of incompatible ingredients
WO2002058835A1 (en) * 2001-01-26 2002-08-01 Howmedica Osteonics Corp. Apparatus for mixing a liquid and dry powered components
WO2002100331A2 (en) 2001-06-08 2002-12-19 Wyeth Calcium phosphate delivery vehicles for osteoinductive proteins
US6521264B1 (en) * 1998-03-20 2003-02-18 Teknimed Method for preparing a biomaterial based on hydroxyapatite, resulting biomaterial and surgical or dental use
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
US20030065400A1 (en) * 2001-04-12 2003-04-03 Beam Heather Ann Method and apparatus for engineered regenrative biostructures such as hydroxyapatite substrates for bone healing applications
US6547866B1 (en) 2000-10-30 2003-04-15 Howmedica Osteonics Corp. Porous calcium phosphate cement
US6558709B2 (en) 2001-01-05 2003-05-06 Howmedica Osteonics Corp. Calcium phosphate composition and method of preparing same
US6592251B2 (en) 2001-01-26 2003-07-15 Howmedica Osteonics Corp. Cement mixing and dispensing device
US6626912B2 (en) 2000-11-21 2003-09-30 Stryker Trauma Gmbh Process for mixing and dispensing a flowable substance
US20030216777A1 (en) * 2002-05-16 2003-11-20 Yin-Chun Tien Method of enhancing healing of interfacial gap between bone and tendon or ligament
US20040003757A1 (en) * 1999-07-14 2004-01-08 Cana Lab Corporation Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface
US20040031420A1 (en) * 2000-07-13 2004-02-19 Lin Jiin-Huey Chern Calcium phosphate cement, use and preparation thereof
EP1439153A1 (en) * 2003-01-17 2004-07-21 Howmedica Osteonics Corp. Calcium phosphate cement precursors
US20040146543A1 (en) * 2002-08-12 2004-07-29 Shimp Lawrence A. Synthesis of a bone-polymer composite material
US6793725B2 (en) 2001-01-24 2004-09-21 Ada Foundation Premixed calcium phosphate cement pastes
US20040250729A1 (en) * 2003-06-16 2004-12-16 Jang Bor Z. Fast-setting carbonated hydroxyapatite compositions and uses
US20050027033A1 (en) * 2003-02-04 2005-02-03 David Knaack Polyurethanes for osteoimplants
US20050074415A1 (en) * 2001-01-24 2005-04-07 Ada Foundation Rapid-hardening calcium phosphate cement compositions
US20050076813A1 (en) * 1999-07-14 2005-04-14 Calcitec, Inc. Process for producing fast-setting, bioresorbable calcium phosphate cements
US20050085922A1 (en) * 2003-10-17 2005-04-21 Shappley Ben R. Shaped filler for implantation into a bone void and methods of manufacture and use thereof
US20050084542A1 (en) * 2003-04-11 2005-04-21 Rosenberg Aron D. Osteoinductive bone material
US20050101964A1 (en) * 2003-11-07 2005-05-12 Calcitec, Inc. Spinal fusion procedure using an injectable bone substitute
US20050186353A1 (en) * 2004-02-19 2005-08-25 Calcitec, Inc. Method for making a porous calcium phosphate article
US20050209696A1 (en) * 2004-01-16 2005-09-22 Jo-Wen Lin Implant frames for use with settable materials and related methods of use
US6953594B2 (en) 1996-10-10 2005-10-11 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US20050239015A1 (en) * 2002-10-04 2005-10-27 Dragan William B Pre-dosed applicator and applicator system
US20050267587A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US6972130B1 (en) 1996-10-16 2005-12-06 Etex Corporation Bioceramic compositions
US20050268821A1 (en) * 2000-07-13 2005-12-08 Cana Lab Corporation Tetracalcium phosphate (TTCP) with surface whiskers and method of making same
US20050274282A1 (en) * 2000-07-13 2005-12-15 Lin Jiin-Huey C Calcium phosphate cements made from (TTCP) with surface whiskers and process for preparing same
US20050283255A1 (en) * 2001-06-04 2005-12-22 Perry Geremakis Tissue-derived mesh for orthopedic regeneration
US20060008522A1 (en) * 1995-01-09 2006-01-12 J. Rettenmaier & Soehne Gmbh + Co. Kg Pharmaceutical excipient having improved compressibility
US20060015184A1 (en) * 2004-01-30 2006-01-19 John Winterbottom Stacking implants for spinal fusion
WO2006030054A1 (en) 2004-08-12 2006-03-23 Universitat Politècnica De Catalunya Injectable, self-setting calcium phosphate foam
US20060084602A1 (en) * 2004-10-14 2006-04-20 Lynch Samuel E Platelet-derived growth factor compositions and methods of use thereof
US20060115437A1 (en) * 2004-11-26 2006-06-01 Robert Hayman Dental whitening compositions
US20060216323A1 (en) * 2003-02-04 2006-09-28 David Knaack Polyurethanes for osteoimplants
US7118705B2 (en) 2003-08-05 2006-10-10 Calcitec, Inc. Method for making a molded calcium phosphate article
US20060225620A1 (en) * 2005-04-08 2006-10-12 Howmedical Leibinger, Inc. D/B/A A Corporation Of Stryker Leibinger Micro Implants Calcium phosphate cement
US20060225621A1 (en) * 2005-04-08 2006-10-12 Howmedica Leibinger Inc. Injectable calcium phosphate cement
US20060240121A1 (en) * 1996-10-16 2006-10-26 Lee Dosuk D Chemotherapeutic composition using nanocrystalline calcium phosphate paste
US7150879B1 (en) 1995-05-19 2006-12-19 Etex Corporation Neutral self-setting calcium phosphate paste
WO2005077049A3 (en) * 2004-02-10 2007-01-18 Univ New York Macroporous, resorbable and injectible calcium phosphate-based cements (mcpc) for bone repair, augmentation, regeneration, and osteoporosis treatment
US7169373B2 (en) 1999-07-14 2007-01-30 Calcitec, Inc. Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface and process for preparing the same
US20070129807A1 (en) * 2004-10-14 2007-06-07 Lynch Samuel E Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
US20070191963A1 (en) * 2002-12-12 2007-08-16 John Winterbottom Injectable and moldable bone substitute materials
US7270705B2 (en) 1999-07-14 2007-09-18 Jiin-Huey Chern Lin Method of increasing working time of tetracalcium phosphate cement paste
US20080028992A1 (en) * 2004-04-15 2008-02-07 Lee Dosuk D Delayed-Setting Calcium Phosphate Pastes
US20080050408A1 (en) * 2004-11-26 2008-02-28 Discus Dental, Llc Dental Whitening Compositions
US20080050407A1 (en) * 2006-02-03 2008-02-28 Haas Michael S Oral care products comprising buffer systems for improved mineralization/remineralization benefits
US20080069852A1 (en) * 2006-01-19 2008-03-20 Shimp Lawrence A Porous osteoimplant
US20080109003A1 (en) * 2006-11-08 2008-05-08 Peckham Steven M Methods of employing calcium phosphate cement compositions and osteoinductive proteins to effect vertebrae interbody fusion absent an interbody device
US20080195476A1 (en) * 2007-02-09 2008-08-14 Marchese Michael A Abandonment remarketing system
US20090036564A1 (en) * 2007-08-03 2009-02-05 Feng-Huei Lin Bio-Degenerable Bone Cement and Manufacturing Method thereof
US20090061002A1 (en) * 2007-09-05 2009-03-05 Venbrocks Rudolf A Calcium phospate based delivery of growth and differentiation factors to compromised bone
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US20090232890A1 (en) * 2008-02-07 2009-09-17 Lynch Samuel E Compositions and methods for distraction osteogenesis
US20100082072A1 (en) * 2008-03-28 2010-04-01 Sybert Daryl R Bone anchors for orthopedic applications
US20100112032A1 (en) * 2008-10-30 2010-05-06 Guelcher Scott A Bone/Polyurethane Composites and Methods Thereof
US20100121459A1 (en) * 2008-11-12 2010-05-13 Garigapati Venkat R Tetra Calcium Phosphate Based Organophosphorus Compositions and Methods
US20100174368A1 (en) * 2008-09-09 2010-07-08 Lynch Samuel E Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US20100183515A1 (en) * 2006-06-30 2010-07-22 Hart Charles E Compositions and methods for treating the vertebral column
US20100212545A1 (en) * 2001-01-24 2010-08-26 Ada Foundation Calcium-containing restoration materials
US7799754B2 (en) 2004-10-14 2010-09-21 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
US20100247651A1 (en) * 2009-03-05 2010-09-30 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects
EP2374471A1 (en) 2003-09-12 2011-10-12 Wyeth LLC Injectable hardenable calcium phosphate pastes for delivery of osteogenic proteins
US8106008B2 (en) 2006-11-03 2012-01-31 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
WO2012129234A1 (en) 2011-03-21 2012-09-27 Endo Pharmaceuticals Inc. Urethral anastomosis device and method
US8492335B2 (en) 2010-02-22 2013-07-23 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US20140046454A1 (en) * 2008-07-25 2014-02-13 Smith & Nephew, Inc. Fracture fixation systems
WO2014047061A1 (en) 2012-09-18 2014-03-27 Endo Pharmaceuticals Inc. Urethral anastomosis device
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
WO2014159186A1 (en) 2013-03-14 2014-10-02 Endo Pharmaceuticals Inc. Urethral anastomosis device
US9265857B2 (en) 2010-05-11 2016-02-23 Howmedica Osteonics Corp. Organophosphorous, multivalent metal compounds, and polymer adhesive interpenetrating network compositions and methods
WO2016140782A1 (en) 2015-03-04 2016-09-09 Modern Ideas LLC Stabilized calcium phosphate and methods of forming same
US9642891B2 (en) 2006-06-30 2017-05-09 Biomimetic Therapeutics, Llc Compositions and methods for treating rotator cuff injuries
US9801946B2 (en) 2008-10-30 2017-10-31 Vanderbilt University Synthetic polyurethane composite
WO2018022553A1 (en) 2016-07-25 2018-02-01 Cerapedics, Inc. Peptide-coated calcium phosphate particles
US9956314B2 (en) 2016-01-26 2018-05-01 Modern Ideas LLC Adhesive for use with bone and bone-like structures
US10182973B2 (en) 2010-11-10 2019-01-22 Stryker European Holdings I, Llc Polymeric bone foam composition and method
US10383807B2 (en) * 2016-05-20 2019-08-20 The Procter & Gamble Company Regimen for providing smooth tooth feel

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2008010A1 (en) * 1970-02-20 1971-08-26 Schneider, & Co , 5020 Frechen Bone and teeth substitutes
US3679360A (en) * 1970-06-26 1972-07-25 Nasa Process for the preparation of brushite crystals
US3787900A (en) * 1971-06-09 1974-01-29 Univ Iowa State Res Found Artificial bone or tooth prosthesis material
US3913229A (en) * 1974-02-25 1975-10-21 Miter Inc Dental treatments
US4097935A (en) * 1976-07-21 1978-07-04 Sterling Drug Inc. Hydroxylapatite ceramic
US4497075A (en) * 1979-10-08 1985-02-05 Mitsubishi Mining & Cement Co., Ltd. Filler for filling in defects or hollow portions of bones
US4599085A (en) * 1979-07-11 1986-07-08 Neodontics, Inc. Bone implant member for prostheses and bone connecting elements and process for the production thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2008010A1 (en) * 1970-02-20 1971-08-26 Schneider, & Co , 5020 Frechen Bone and teeth substitutes
US3679360A (en) * 1970-06-26 1972-07-25 Nasa Process for the preparation of brushite crystals
US3787900A (en) * 1971-06-09 1974-01-29 Univ Iowa State Res Found Artificial bone or tooth prosthesis material
US3913229A (en) * 1974-02-25 1975-10-21 Miter Inc Dental treatments
US4097935A (en) * 1976-07-21 1978-07-04 Sterling Drug Inc. Hydroxylapatite ceramic
US4599085A (en) * 1979-07-11 1986-07-08 Neodontics, Inc. Bone implant member for prostheses and bone connecting elements and process for the production thereof
US4497075A (en) * 1979-10-08 1985-02-05 Mitsubishi Mining & Cement Co., Ltd. Filler for filling in defects or hollow portions of bones

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
"NASA and Dentistry"(1977).
Briner et al., "Significance of Enamel Remineralization," J. Dent. Res. 11 (Supp. 1): 59-84 (1974).
Briner et al., Significance of Enamel Remineralization, J. Dent. Res. 11 (Supp. 1): 59 84 (1974). *
Brown and Chow, Singular Points in the Chemistry of Teeth, IADR Abstract No. 120 (1975). *
Brown et al, "Crystallography of Tetracalcium Phosphate," J. Res. Nat. Bur. Stands. 69A: 547-551 (1965).
Brown et al, Crystallography of Tetracalcium Phosphate, J. Res. Nat. Bur. Stands. 69A: 547 551 (1965). *
Brown, Solubilities of Phosphates and Other Sparingly Soluble Compounds, from Griffith et al, Environmental Phosphorous Handbook (John Wiley & Sons, New York, 1976. *
Driskell et al., "Development of Ceramic and Ceramic Composite Devices for Maxillofacial Application," J. Biomed. Mat. Res. 6: 345-361 (1972).
Driskell et al., Development of Ceramic and Ceramic Composite Devices for Maxillofacial Application, J. Biomed. Mat. Res. 6: 345 361 (1972). *
Gelhard et al, "Rehardening of Artificial Enamel Lesions in vivo," Caries Res. 13:80-83 (1979).
Gelhard et al, Rehardening of Artificial Enamel Lesions in vivo , Caries Res. 13:80 83 (1979). *
Gregory et al, "Solubility of --Ca3 (PO4)2 in the System Ca(OH)2 --H3 PO4 --H2 O at 5, 15, 25 and 37[C," J. Res. Nat. Bur. Stand. 78A: 667-674 (1974).
Gregory et al, "Solubility of CaHPO4.2H2 O in the System Ca(OH)2 --H3 PO4 --H2 O at 5, 15, 25, and 37.5 [C.," J. Res. Nat. Bur. Stand. 74A: 461-475 (1970).
Gregory et al, Solubility of Ca 3 (PO 4 ) 2 in the System Ca(OH) 2 H 3 PO 4 H 2 O at 5, 15, 25 and 37 C, J. Res. Nat. Bur. Stand. 78A: 667 674 (1974). *
Gregory et al, Solubility of CaHPO 4 .2H 2 O in the System Ca(OH) 2 H 3 PO 4 H 2 O at 5, 15, 25, and 37.5 C., J. Res. Nat. Bur. Stand. 74A: 461 475 (1970). *
Guide to Dental Material and Devices, 7th Ed. (ADA 1974), pp. 49 66. *
Guide to Dental Material and Devices, 7th Ed. (ADA 1974), pp. 49-66.
Hiatt et al, "Root Preparation I. Obturation of Dentinal Tubules in Treatment of Root Hyper-Sensitivity," J. Periodontal. 43: 373-380 (1972).
Hiatt et al, Root Preparation I. Obturation of Dentinal Tubules in Treatment of Root Hyper Sensitivity, J. Periodontal. 43: 373 380 (1972). *
LeGeros et al, "Apatitic Calcium Phosphates: Possible Dental Restorative Materials,"IADR Abstract No. 1482 (1982).
LeGeros et al, Apatitic Calcium Phosphates: Possible Dental Restorative Materials, IADR Abstract No. 1482 (1982). *
Levine, "Remineralisation of Natural Carious Lesions of Enamel in vitro," Brit. Dent. J., 137: 132-134 (1974).
Levine, Remineralisation of Natural Carious Lesions of Enamel in vitro, Brit. Dent. J., 137: 132 134 (1974). *
McDowell et al, "Solubility of Ca5 (PO4)3 OH in the System Ca(OH)2 --H3 PO4 --H2 O at 5, 15, 25 and 37.5[C," J. Res. Nat. Bur. Stand. 81A: 273-281 (1977).
McDowell et al, Solubility of Ca 5 (PO 4 ) 3 OH in the System Ca(OH) 2 H 3 PO 4 H 2 O at 5, 15, 25 and 37.5 C, J. Res. Nat. Bur. Stand. 81A: 273 281 (1977). *
McDowell et al., "Solubility Study of Calcium Hydrogen Phosphate. Ion Pair Formation," Inorg. Chem. 10: 1638-1643 (1971).
McDowell et al., Solubility Study of Calcium Hydrogen Phosphate. Ion Pair Formation, Inorg. Chem. 10: 1638 1643 (1971). *
Moreno et al, "Stability of Dicalcium Phosphate Dihydrate in Aqueous Solutions and Solubility of Octacalcium Phosphate," Soil Sci. Soc. Am. Proc. 21: 99-102 (1960).
Moreno et al, Stability of Dicalcium Phosphate Dihydrate in Aqueous Solutions and Solubility of Octacalcium Phosphate, Soil Sci. Soc. Am. Proc. 21: 99 102 (1960). *
NASA and Dentistry (1977). *
Patel et al, "Solubility of CaHPO4.2H2 O in the Quaternary System Ca(OH)2 --H3 PO4 --NaCl--H2 O at 25[C," J. Rest. Nat. Bur. Stands. 78A: 675-681 (1974).
Patel et al, Solubility of CaHPO 4 .2H 2 O in the Quaternary System Ca(OH) 2 H 3 PO 4 NaCl H 2 O at 25 C, J. Rest. Nat. Bur. Stands. 78A: 675 681 (1974). *
Pickel et al, "The Effect of a Chewing Gum Containing Dicalcium Phosphate on Salivary Calcium and Phosphate," Ala J. Med. Sci. 2: 286-287 (1965).
Pickel et al, The Effect of a Chewing Gum Containing Dicalcium Phosphate on Salivary Calcium and Phosphate, Ala J. Med. Sci. 2: 286 287 (1965). *
Silverstone, "Remineralization Phenomena," Caries Res. 11 (Supp. 1): 59-84 (1977).
Silverstone, Remineralization Phenomena, Caries Res. 11 (Supp. 1): 59 84 (1977). *
Zimmerman et al, The Effect of Remineralization Fluids on Carious Lesions in vitro, IADR Abstract No. 282 (1979). *

Cited By (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962028A (en) 1988-04-20 1999-10-05 Norian Corporation Carbonated hydroxyapatite compositions and uses
US6002065A (en) 1988-04-20 1999-12-14 Norian Corporation Kits for preparing calcium phosphate minerals
US5820632A (en) * 1988-04-20 1998-10-13 Norian Corporation Prepared calcium phosphate composition and method
US5900254A (en) 1988-04-20 1999-05-04 Norian Corporation Carbonated hydroxyapatite compositions and uses
US5952010A (en) 1988-04-20 1999-09-14 Norian Corporation Paste compositions capable of setting into carbonated apatite
US5336264A (en) * 1988-04-20 1994-08-09 Norian Corporation Situ prepared calcium phosphate composition and method
US6005162A (en) 1988-04-20 1999-12-21 Norian Corporation Methods of repairing bone
US5068100A (en) * 1989-03-09 1991-11-26 The Procter & Gamble Company Anticalculus compositions
US5460803A (en) * 1989-05-24 1995-10-24 American Dental Association Health Foundation Methods and compositions for mineralizing and fluoridating calcified tissues
US5437857A (en) * 1989-05-24 1995-08-01 American Dental Association Health Foundation Methods and compositions for mineralizing and fluoridating calcified tissues
US5534244A (en) * 1989-05-24 1996-07-09 Tung; Ming S. Methods and compositions for mineralizing and/or fluoridating calcified tissues with amorphous strontium compounds
US5145520A (en) * 1989-08-29 1992-09-08 Kyoto University Bioactive cement
US5128169A (en) * 1990-01-08 1992-07-07 Sumitomo Chemical Company, Limited Method for forming hydroxyapatite coating film
US5782971A (en) * 1991-06-28 1998-07-21 Norian Corporation Calcium phosphate cements comprising amorophous calcium phosphate
US5258044A (en) * 1992-01-30 1993-11-02 Etex Corporation Electrophoretic deposition of calcium phosphate material on implants
US5401783A (en) * 1992-06-15 1995-03-28 American Dental Association Health Foundation Adhesion-promoting agents incorporating polyvalent cations
WO1994002411A1 (en) * 1992-07-20 1994-02-03 Amp Medical Method for preparing phosphocalcium hydroxyapatite, use thereof for bone or tooth filling or for moulding parts, and products used therein
FR2693716A1 (en) * 1992-07-20 1994-01-21 Toulouse Inst Nat Polytech Process for obtaining phosphocalcic hydroxyapatite, applications for bone or dental filling, or molding of parts, and products used.
US6334891B1 (en) 1992-10-16 2002-01-01 Norian Corporation Paste compositions capable of setting into carbonated apatite
US5522893A (en) * 1993-03-12 1996-06-04 American Dental Association Health Foundation Calcium phosphate hydroxyapatite precursor and methods for making and using the same
WO1994020064A1 (en) * 1993-03-12 1994-09-15 American Dental Association Health Foundation Calcium phosphate hydroxyapatite precursor and methods for making and using the same
US5542973A (en) * 1993-03-12 1996-08-06 The American Dental Association Health Foundation Calcium phosphate hydroxyapatite precursor and methods for making and using the same
US5545254A (en) * 1993-03-12 1996-08-13 The American Dental Association Health Foundation Calcium phosphate hydroxyapatite precursor and methods for making and using the same
US5427768A (en) * 1993-06-23 1995-06-27 American Dental Association Health Foundation Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
EP0639366A1 (en) * 1993-08-19 1995-02-22 Kingstar Technology Limited (Uk) Hydroxyapatite cement as bone or tooth replacement
US5476647A (en) * 1993-09-13 1995-12-19 American Dental Association Health Foundation Complex calcium and fluoride containing mouth rinses, dentifrices, and chewable tablets
US5997624A (en) 1993-09-24 1999-12-07 American Dental Association Health Foundation Self-setting calcium phosphate cements and methods for preparing and using them
US5525148A (en) * 1993-09-24 1996-06-11 American Dental Association Health Foundation Self-setting calcium phosphate cements and methods for preparing and using them
US5954867A (en) 1993-09-24 1999-09-21 American Dental Health Foundation Association Self setting calcium phosphate cements and methods for preparing and using them
US5496399A (en) * 1994-08-23 1996-03-05 Norian Corporation Storage stable calcium phosphate cements
WO1996006041A1 (en) * 1994-08-23 1996-02-29 Norian Corporation Storage stable calcium phosphate cements
US5846312A (en) * 1994-08-23 1998-12-08 Norian Corporation Storage stable calcium phosphate cements
US20060008522A1 (en) * 1995-01-09 2006-01-12 J. Rettenmaier & Soehne Gmbh + Co. Kg Pharmaceutical excipient having improved compressibility
US5550172A (en) * 1995-02-07 1996-08-27 Ethicon, Inc. Utilization of biocompatible adhesive/sealant materials for securing surgical devices
WO1996025914A1 (en) * 1995-02-24 1996-08-29 American Dental Association Health Foundation Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
US6117456A (en) 1995-05-19 2000-09-12 Etex Corporation Methods and products related to the physical conversion of reactive amorphous calcium phosphate
US5650176A (en) * 1995-05-19 1997-07-22 Etex Corporation Synthesis of reactive amorphous calcium phosphates
US6027742A (en) 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US6544290B1 (en) 1995-05-19 2003-04-08 Etex Corporation Cell seeding of ceramic compositions
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
US6139578A (en) 1995-05-19 2000-10-31 Etex Corporation Preparation of cell seeded ceramic compositions
US6214368B1 (en) * 1995-05-19 2001-04-10 Etex Corporation Bone substitution material and a method of its manufacture
US6277151B1 (en) 1995-05-19 2001-08-21 Etex Corporation Cartilage growth from cell seeded ceramic compositions
US6287341B1 (en) 1995-05-19 2001-09-11 Etex Corporation Orthopedic and dental ceramic implants
US5683461A (en) * 1995-05-19 1997-11-04 Etex Corporation Synthesis of reactive amorphous calcium phosphates
US6331312B1 (en) 1995-05-19 2001-12-18 Etex Corporation Bioresorbable ceramic composites
US7150879B1 (en) 1995-05-19 2006-12-19 Etex Corporation Neutral self-setting calcium phosphate paste
US6364909B1 (en) 1995-07-18 2002-04-02 Iowa State University Research Foundation, Inc. Method of restructuring bone
US6312467B1 (en) 1995-07-18 2001-11-06 Iowa State University Research Foundation, Inc. Method of restructuring bone
US6719793B2 (en) 1995-07-18 2004-04-13 Iowa State University Research Foundation, Inc. Method of restructuring bone
US6953594B2 (en) 1996-10-10 2005-10-11 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US8728536B2 (en) 1996-10-16 2014-05-20 Etex Corporation Chemotherapeutic composition using nanocrystalline calcium phosphate paste
US6972130B1 (en) 1996-10-16 2005-12-06 Etex Corporation Bioceramic compositions
US20060240121A1 (en) * 1996-10-16 2006-10-26 Lee Dosuk D Chemotherapeutic composition using nanocrystalline calcium phosphate paste
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US5980625A (en) 1997-03-13 1999-11-09 Ngk Spark Plug Co., Ltd. Calcium phosphate composition and a setting solution therefor
US6521264B1 (en) * 1998-03-20 2003-02-18 Teknimed Method for preparing a biomaterial based on hydroxyapatite, resulting biomaterial and surgical or dental use
US20030108589A1 (en) * 1998-03-20 2003-06-12 Teknimed Method for preparing a biomaterial based on hydroxyapatite, resulting biomaterial and surgical or dental use
US6051061A (en) 1998-03-23 2000-04-18 Ngk Spark Plug Co., Ltd. Calcium phosphate cements and calcium phosphate cement compositions
US5858333A (en) * 1998-08-07 1999-01-12 Enamelon, Inc. Two-part oral products and methods of using same to remineralize teeth
US7270705B2 (en) 1999-07-14 2007-09-18 Jiin-Huey Chern Lin Method of increasing working time of tetracalcium phosphate cement paste
US7279038B2 (en) 1999-07-14 2007-10-09 Calcitec, Inc. Process for affecting the setting and working time of bioresorbable calcium phosphate cements
US7258734B2 (en) 1999-07-14 2007-08-21 Calcitec, Inc. Injectable calcium phosphate cements and the preparation and use thereof
US20040003757A1 (en) * 1999-07-14 2004-01-08 Cana Lab Corporation Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface
US7066999B2 (en) 1999-07-14 2006-06-27 Calcitec, Inc. Process for producing fast-setting, bioresorbable calcium phosphate cements
US20060011099A1 (en) * 1999-07-14 2006-01-19 Lin Jiin-Huey C Process for affecting the setting and working time of bioresorbable calcium phosphate cements
US7258735B2 (en) 1999-07-14 2007-08-21 Calcitec, Inc. Process for affecting the setting and working time of bioresorbable calcium phosphate cements
US20060011100A1 (en) * 1999-07-14 2006-01-19 Lin Jiin-Huey C Process for affecting the setting and working time of bioresorbable calcium phosphate cements
US7201797B2 (en) 1999-07-14 2007-04-10 Calcitec, Inc. Process for affecting the setting and working time of, bioresorbable calcium phosphate cements
US20050279256A1 (en) * 1999-07-14 2005-12-22 Lin Jiin-Huey C Process for affecting the setting and working time of bioresorbable calcium phosphate cements
US20050274289A1 (en) * 1999-07-14 2005-12-15 Lin Jiin-Huey C Process for affecting the setting and working time of, bioresorbable calcium phosphate cements
US20050271742A1 (en) * 1999-07-14 2005-12-08 Calcitec, Inc. Injectable calcium phosphate cements and the preparation and use thereof
US20050268819A1 (en) * 1999-07-14 2005-12-08 Cana Lab Corporation Injectable calcium phosphate cements and the preparation and use thereof
US7186294B2 (en) 1999-07-14 2007-03-06 Calcitec, Inc. Process for affecting the setting and working time of bioresorbable calcium phosphate cements
US7169373B2 (en) 1999-07-14 2007-01-30 Calcitec, Inc. Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface and process for preparing the same
US20050076813A1 (en) * 1999-07-14 2005-04-14 Calcitec, Inc. Process for producing fast-setting, bioresorbable calcium phosphate cements
US20050279252A1 (en) * 2000-07-13 2005-12-22 Cana Lab Corporation Tetracalcium phosphate (TTCP) with surface whiskers and method of making same
US7976874B2 (en) 2000-07-13 2011-07-12 Jiin-Huey Chern Lin Injectable calcium phosphate cements and the preparation and use thereof
US7214265B2 (en) 2000-07-13 2007-05-08 Calcitec, Inc. Injectable calcium phosphate cements and the preparation and use thereof
US7182928B2 (en) 2000-07-13 2007-02-27 Calcitec, Inc. Calcium phosphate cements made from (TTCP) with surface whiskers and process for preparing same
US20040031420A1 (en) * 2000-07-13 2004-02-19 Lin Jiin-Huey Chern Calcium phosphate cement, use and preparation thereof
US7160381B2 (en) 2000-07-13 2007-01-09 Calcitec, Inc. Tetracalcium phosphate (TTCP) with surface whiskers and method of making same
US7160382B2 (en) 2000-07-13 2007-01-09 Calcitec, Inc. Calcium phosphate cements made from (TTCP) with surface whiskers and process for preparing same
US7094282B2 (en) 2000-07-13 2006-08-22 Calcitec, Inc. Calcium phosphate cement, use and preparation thereof
US7156915B2 (en) 2000-07-13 2007-01-02 Calcitec, Inc. Tetracalcium phosphate (TTCP) with surface whiskers and method of making same
US7204876B2 (en) 2000-07-13 2007-04-17 Calcitec, Inc. Calcium phosphate cements made from (TTCP) with surface whiskers and process for preparing same
US20050271740A1 (en) * 2000-07-13 2005-12-08 Cana Lab Corporation Injectable calcium phosphate cements and the preparation and use thereof
US20050271741A1 (en) * 2000-07-13 2005-12-08 Cana Lab Corporation Injectable calcium phosphate cements and the preparation and use thereof
US20050274287A1 (en) * 2000-07-13 2005-12-15 Lin Jiin-Huey C Calcium phosphate cements made from (TTCP) with surface whiskers and process for preparing same
US20050274286A1 (en) * 2000-07-13 2005-12-15 Lin Jiin-Huey C Calcium phosphate cements made from (TTCP) with surface whiskers and process for preparing same
US20050274282A1 (en) * 2000-07-13 2005-12-15 Lin Jiin-Huey C Calcium phosphate cements made from (TTCP) with surface whiskers and process for preparing same
US20050268821A1 (en) * 2000-07-13 2005-12-08 Cana Lab Corporation Tetracalcium phosphate (TTCP) with surface whiskers and method of making same
US20050268820A1 (en) * 2000-07-13 2005-12-08 Calcitec, Inc. Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface
US7182937B2 (en) 2000-10-13 2007-02-27 Block Drug Company, Inc. Anhydrous dentrifice formulations for the delivery of incompatible ingredients
US20040047814A1 (en) * 2000-10-13 2004-03-11 Jin Xu Anhydrous dentrifice formulations for the delivery of incompatible ingredients
WO2002030381A1 (en) * 2000-10-13 2002-04-18 Block Drug Company, Inc. Anhydrous dentifrice formulations for the delivery of incompatible ingredients
US6547866B1 (en) 2000-10-30 2003-04-15 Howmedica Osteonics Corp. Porous calcium phosphate cement
US6670293B2 (en) 2000-10-30 2003-12-30 Howmedica Osteonics Corp. Porous calcium phosphate cement
US6626912B2 (en) 2000-11-21 2003-09-30 Stryker Trauma Gmbh Process for mixing and dispensing a flowable substance
US6849275B2 (en) 2001-01-05 2005-02-01 Howmedica Osteonics Corp. Calcium phosphate composition and method of preparing same
US6558709B2 (en) 2001-01-05 2003-05-06 Howmedica Osteonics Corp. Calcium phosphate composition and method of preparing same
US6793725B2 (en) 2001-01-24 2004-09-21 Ada Foundation Premixed calcium phosphate cement pastes
US8282396B2 (en) 2001-01-24 2012-10-09 Ada Foundation Calcium-containing restoration materials
US20050074415A1 (en) * 2001-01-24 2005-04-07 Ada Foundation Rapid-hardening calcium phosphate cement compositions
US7294187B2 (en) * 2001-01-24 2007-11-13 Ada Foundation Rapid-hardening calcium phosphate cement compositions
US20100212545A1 (en) * 2001-01-24 2010-08-26 Ada Foundation Calcium-containing restoration materials
WO2002058835A1 (en) * 2001-01-26 2002-08-01 Howmedica Osteonics Corp. Apparatus for mixing a liquid and dry powered components
US6592251B2 (en) 2001-01-26 2003-07-15 Howmedica Osteonics Corp. Cement mixing and dispensing device
US6494611B2 (en) 2001-01-26 2002-12-17 Howmedica Osteonics Corp. Apparatus for mixing a liquid and dry powdered components
US20030065400A1 (en) * 2001-04-12 2003-04-03 Beam Heather Ann Method and apparatus for engineered regenrative biostructures such as hydroxyapatite substrates for bone healing applications
US7122057B2 (en) 2001-04-12 2006-10-17 Therics, Llc Method and apparatus for engineered regenerative biostructures such as hydroxyapatite substrates for bone healing applications
US8740987B2 (en) 2001-06-04 2014-06-03 Warsaw Orthopedic, Inc. Tissue-derived mesh for orthopedic regeneration
US20050283255A1 (en) * 2001-06-04 2005-12-22 Perry Geremakis Tissue-derived mesh for orthopedic regeneration
WO2002100331A2 (en) 2001-06-08 2002-12-19 Wyeth Calcium phosphate delivery vehicles for osteoinductive proteins
EP2260860A1 (en) 2001-06-08 2010-12-15 Wyeth LLC Calcium phosphate delivery vehicles for osteoinduktive proteins
US20030216777A1 (en) * 2002-05-16 2003-11-20 Yin-Chun Tien Method of enhancing healing of interfacial gap between bone and tendon or ligament
US20040146543A1 (en) * 2002-08-12 2004-07-29 Shimp Lawrence A. Synthesis of a bone-polymer composite material
US8771719B2 (en) 2002-08-12 2014-07-08 Warsaw Orthopedic, Inc. Synthesis of a bone-polymer composite material
US20050239015A1 (en) * 2002-10-04 2005-10-27 Dragan William B Pre-dosed applicator and applicator system
US9333080B2 (en) 2002-12-12 2016-05-10 Warsaw Orthopedic, Inc. Injectable and moldable bone substitute materials
US9107751B2 (en) 2002-12-12 2015-08-18 Warsaw Orthopedic, Inc. Injectable and moldable bone substitute materials
US10080661B2 (en) 2002-12-12 2018-09-25 Warsaw Orthopedic, Inc. Injectable and moldable bone substitute materials
US20070191963A1 (en) * 2002-12-12 2007-08-16 John Winterbottom Injectable and moldable bone substitute materials
US20040141903A1 (en) * 2003-01-17 2004-07-22 Howmedica Osteonics Corp. Calcium phosphate cement precursors
EP1439153A1 (en) * 2003-01-17 2004-07-21 Howmedica Osteonics Corp. Calcium phosphate cement precursors
US9789223B2 (en) 2003-02-04 2017-10-17 Warsaw Orthopedic, Inc. Polyurethanes for osteoimplants
US9993579B2 (en) 2003-02-04 2018-06-12 Warsaw Orthopedic, Inc. Polyurethanes for osteoimplants
US20060216323A1 (en) * 2003-02-04 2006-09-28 David Knaack Polyurethanes for osteoimplants
US10322209B2 (en) 2003-02-04 2019-06-18 Warsaw Orthopedic, Inc. Polyurethanes for osteoimplants
US8425893B2 (en) 2003-02-04 2013-04-23 Warsaw Orthopedic, Inc. Polyurethanes for osteoimplants
US9327052B2 (en) 2003-02-04 2016-05-03 Warsaw Orthopedic, Inc. Polyurethanes for osteoimplants
US7985414B2 (en) 2003-02-04 2011-07-26 Warsaw Orthopedic, Inc. Polyurethanes for osteoimplants
US20050027033A1 (en) * 2003-02-04 2005-02-03 David Knaack Polyurethanes for osteoimplants
US8002843B2 (en) 2003-02-04 2011-08-23 Warsaw Orthopedic, Inc. Polyurethanes for osteoimplants
US20050084542A1 (en) * 2003-04-11 2005-04-21 Rosenberg Aron D. Osteoinductive bone material
US8221781B2 (en) 2003-04-11 2012-07-17 Etex Corporation Osteoinductive bone material
US20080188946A1 (en) * 2003-04-11 2008-08-07 Etex Corporation Osteoinductive bone material
US8454988B2 (en) 2003-04-11 2013-06-04 Etex Corporation Osteoinductive bone material
US20040250729A1 (en) * 2003-06-16 2004-12-16 Jang Bor Z. Fast-setting carbonated hydroxyapatite compositions and uses
US7118705B2 (en) 2003-08-05 2006-10-10 Calcitec, Inc. Method for making a molded calcium phosphate article
EP2374471A1 (en) 2003-09-12 2011-10-12 Wyeth LLC Injectable hardenable calcium phosphate pastes for delivery of osteogenic proteins
US20050085922A1 (en) * 2003-10-17 2005-04-21 Shappley Ben R. Shaped filler for implantation into a bone void and methods of manufacture and use thereof
US20050101964A1 (en) * 2003-11-07 2005-05-12 Calcitec, Inc. Spinal fusion procedure using an injectable bone substitute
WO2005074453A3 (en) * 2004-01-16 2006-11-16 Ada Foundation Rapid-hardening calcium phosphate cement compositions
US20050209696A1 (en) * 2004-01-16 2005-09-22 Jo-Wen Lin Implant frames for use with settable materials and related methods of use
EP2266634A2 (en) 2004-01-16 2010-12-29 Ada Foundation Rapid-hardening calcium phosphate cement compositions
US8012210B2 (en) 2004-01-16 2011-09-06 Warsaw Orthopedic, Inc. Implant frames for use with settable materials and related methods of use
US20060015184A1 (en) * 2004-01-30 2006-01-19 John Winterbottom Stacking implants for spinal fusion
WO2005077049A3 (en) * 2004-02-10 2007-01-18 Univ New York Macroporous, resorbable and injectible calcium phosphate-based cements (mcpc) for bone repair, augmentation, regeneration, and osteoporosis treatment
US7119038B2 (en) 2004-02-19 2006-10-10 Calcitec, Inc. Method for making a porous calcium phosphate article
US7097793B2 (en) * 2004-02-19 2006-08-29 Calcitec, Inc. Method for making a porous calcium phosphate article
US7163651B2 (en) 2004-02-19 2007-01-16 Calcitec, Inc. Method for making a porous calcium phosphate article
US7083750B2 (en) * 2004-02-19 2006-08-01 Calcitec, Inc. Method for making a porous calcium phosphate article
US20050186449A1 (en) * 2004-02-19 2005-08-25 Calcitec, Inc. Method for making a porous calcium phosphate article
US20050186354A1 (en) * 2004-02-19 2005-08-25 Lin Jiin-Huey C. Method for making a porous calcium phosphate article
US20050184418A1 (en) * 2004-02-19 2005-08-25 Calcitec, Inc. Method for making a porous calcium phosphate article
US20050186353A1 (en) * 2004-02-19 2005-08-25 Calcitec, Inc. Method for making a porous calcium phosphate article
US8216359B2 (en) 2004-04-15 2012-07-10 Etex Corporation Delayed-setting calcium phosphate pastes
US20080028992A1 (en) * 2004-04-15 2008-02-07 Lee Dosuk D Delayed-Setting Calcium Phosphate Pastes
US20050263930A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7122139B2 (en) * 2004-05-25 2006-10-17 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7115222B2 (en) 2004-05-25 2006-10-03 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050263921A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050263929A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7122138B2 (en) * 2004-05-25 2006-10-17 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050263920A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050263922A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050263931A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7097792B2 (en) 2004-05-25 2006-08-29 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7122140B2 (en) * 2004-05-25 2006-10-17 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7118695B2 (en) * 2004-05-25 2006-10-10 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7128856B2 (en) * 2004-05-25 2006-10-31 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7083749B2 (en) * 2004-05-25 2006-08-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050263927A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050267604A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050267587A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7157027B2 (en) * 2004-05-25 2007-01-02 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7182895B2 (en) 2004-05-25 2007-02-27 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050267592A1 (en) * 2004-05-25 2005-12-01 Jiin-Huey Chern Lin Dual function prosthetic bone implant and method for preparing the same
US20050267588A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050263928A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US20050267593A1 (en) * 2004-05-25 2005-12-01 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
WO2006030054A1 (en) 2004-08-12 2006-03-23 Universitat Politècnica De Catalunya Injectable, self-setting calcium phosphate foam
EP3170505A1 (en) 2004-10-14 2017-05-24 BioMimetic Therapeutics, LLC Platelet-derived growth factor compositions and method of use thereof
US20110117018A1 (en) * 2004-10-14 2011-05-19 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
EP2223698A1 (en) 2004-10-14 2010-09-01 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and method of use thereof
US7799754B2 (en) 2004-10-14 2010-09-21 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
US10258566B2 (en) 2004-10-14 2019-04-16 Biomimetic Therapeutics, Llc Compositions and methods for treating bone
US20070129807A1 (en) * 2004-10-14 2007-06-07 Lynch Samuel E Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
WO2006044334A2 (en) 2004-10-14 2006-04-27 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US11318230B2 (en) 2004-10-14 2022-05-03 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
US11571497B2 (en) 2004-10-14 2023-02-07 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
EP2308501A1 (en) 2004-10-14 2011-04-13 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
EP2308500A1 (en) 2004-10-14 2011-04-13 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US8114841B2 (en) 2004-10-14 2012-02-14 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
US9545377B2 (en) 2004-10-14 2017-01-17 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
US20060084602A1 (en) * 2004-10-14 2006-04-20 Lynch Samuel E Platelet-derived growth factor compositions and methods of use thereof
US11364325B2 (en) 2004-10-14 2022-06-21 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
US20080050408A1 (en) * 2004-11-26 2008-02-28 Discus Dental, Llc Dental Whitening Compositions
US20060115437A1 (en) * 2004-11-26 2006-06-01 Robert Hayman Dental whitening compositions
US20090158964A1 (en) * 2005-04-08 2009-06-25 Howmedica Leibinger Inc. Injectable calcium phosphate cement
US7416602B2 (en) 2005-04-08 2008-08-26 Howmedica Leibinger, Inc. Calcium phosphate cement
US20060225621A1 (en) * 2005-04-08 2006-10-12 Howmedica Leibinger Inc. Injectable calcium phosphate cement
US7892346B2 (en) 2005-04-08 2011-02-22 Howmedica Osteonics Corp. Injectable calcium phosphate cement
US7892347B2 (en) 2005-04-08 2011-02-22 Howmedica Osteonics Corp. Injectable calcium phosphate cement
US20060225620A1 (en) * 2005-04-08 2006-10-12 Howmedical Leibinger, Inc. D/B/A A Corporation Of Stryker Leibinger Micro Implants Calcium phosphate cement
US20100095870A1 (en) * 2005-04-08 2010-04-22 Insley Gerard M Injectable calcium phosphate cement
US7459018B2 (en) 2005-04-08 2008-12-02 Howmedica Leibinger Inc. Injectable calcium phosphate cement
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
US8545858B2 (en) 2005-12-06 2013-10-01 Etex Corporation Porous calcium phosphate bone material
US20080069852A1 (en) * 2006-01-19 2008-03-20 Shimp Lawrence A Porous osteoimplant
US9034356B2 (en) 2006-01-19 2015-05-19 Warsaw Orthopedic, Inc. Porous osteoimplant
US8518383B2 (en) 2006-02-03 2013-08-27 Wm. Wrigley Jr. Company Oral care products comprising buffer systems for improved mineralization/remineralization benefits
US20080050407A1 (en) * 2006-02-03 2008-02-28 Haas Michael S Oral care products comprising buffer systems for improved mineralization/remineralization benefits
US10456450B2 (en) 2006-06-30 2019-10-29 Biomimetic Therapeutics, Llc Compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US20100183515A1 (en) * 2006-06-30 2010-07-22 Hart Charles E Compositions and methods for treating the vertebral column
US9642891B2 (en) 2006-06-30 2017-05-09 Biomimetic Therapeutics, Llc Compositions and methods for treating rotator cuff injuries
US11058801B2 (en) 2006-06-30 2021-07-13 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US8106008B2 (en) 2006-11-03 2012-01-31 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures
US20080109003A1 (en) * 2006-11-08 2008-05-08 Peckham Steven M Methods of employing calcium phosphate cement compositions and osteoinductive proteins to effect vertebrae interbody fusion absent an interbody device
US8388626B2 (en) 2006-11-08 2013-03-05 Warsaw Orthopedic, Inc. Methods of employing calcium phosphate cement compositions and osteoinductive proteins to effect vertebrae interbody fusion absent an interbody device
US20080195476A1 (en) * 2007-02-09 2008-08-14 Marchese Michael A Abandonment remarketing system
US20090036564A1 (en) * 2007-08-03 2009-02-05 Feng-Huei Lin Bio-Degenerable Bone Cement and Manufacturing Method thereof
US20090061002A1 (en) * 2007-09-05 2009-03-05 Venbrocks Rudolf A Calcium phospate based delivery of growth and differentiation factors to compromised bone
EP2033598A1 (en) 2007-09-05 2009-03-11 DePuy-Biotech Gmbh Calcium phosphate based delivery of growth and differentiation factors to compromised bone
US20090232890A1 (en) * 2008-02-07 2009-09-17 Lynch Samuel E Compositions and methods for distraction osteogenesis
US8349796B2 (en) 2008-02-07 2013-01-08 Biomimetic Therapeutics Inc. Methods for treatment of distraction osteogenesis using PDGF
US7943573B2 (en) 2008-02-07 2011-05-17 Biomimetic Therapeutics, Inc. Methods for treatment of distraction osteogenesis using PDGF
US20100082072A1 (en) * 2008-03-28 2010-04-01 Sybert Daryl R Bone anchors for orthopedic applications
US20140046454A1 (en) * 2008-07-25 2014-02-13 Smith & Nephew, Inc. Fracture fixation systems
US20100174368A1 (en) * 2008-09-09 2010-07-08 Lynch Samuel E Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US11135341B2 (en) 2008-09-09 2021-10-05 Biomimetic Therapeutics, Llc Platelet-derived growth factor composition and methods for the treatment of tendon and ligament injuries
US9801946B2 (en) 2008-10-30 2017-10-31 Vanderbilt University Synthetic polyurethane composite
US9333276B2 (en) 2008-10-30 2016-05-10 Vanderbilt University Bone/polyurethane composites and methods thereof
US20100112032A1 (en) * 2008-10-30 2010-05-06 Guelcher Scott A Bone/Polyurethane Composites and Methods Thereof
US8273803B2 (en) 2008-11-12 2012-09-25 Howmedica Osteonics Corp. Tetra calcium phosphate based organophosphorus compositions and methods
US20100121459A1 (en) * 2008-11-12 2010-05-13 Garigapati Venkat R Tetra Calcium Phosphate Based Organophosphorus Compositions and Methods
US8232327B2 (en) 2008-11-12 2012-07-31 Howmedia Osteonics Corp Tetra calcium phosphate based organophosphorus compositions and methods
US20100247651A1 (en) * 2009-03-05 2010-09-30 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects
US11235030B2 (en) 2010-02-22 2022-02-01 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US8492335B2 (en) 2010-02-22 2013-07-23 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US9265857B2 (en) 2010-05-11 2016-02-23 Howmedica Osteonics Corp. Organophosphorous, multivalent metal compounds, and polymer adhesive interpenetrating network compositions and methods
US10286102B2 (en) 2010-05-11 2019-05-14 Howmedica Osteonics Corp Organophosphorous, multivalent metal compounds, and polymer adhesive interpenetrating network compositions and methods
US11185475B2 (en) 2010-11-10 2021-11-30 Stryker European Operations Holdings Llc Polymeric bone foam composition and method
US10182973B2 (en) 2010-11-10 2019-01-22 Stryker European Holdings I, Llc Polymeric bone foam composition and method
US9050163B2 (en) 2011-03-21 2015-06-09 Endo Pharmaceuticals Inc. Urethral anastomosis device and method
WO2012129234A1 (en) 2011-03-21 2012-09-27 Endo Pharmaceuticals Inc. Urethral anastomosis device and method
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
WO2014047061A1 (en) 2012-09-18 2014-03-27 Endo Pharmaceuticals Inc. Urethral anastomosis device
WO2014159186A1 (en) 2013-03-14 2014-10-02 Endo Pharmaceuticals Inc. Urethral anastomosis device
US11116701B2 (en) 2015-03-04 2021-09-14 Modern Ideas LLC Stabilized calcium phosphate
US10219986B2 (en) 2015-03-04 2019-03-05 Modern Ideas LLC Stabilized calcium phosphate and methods of forming same
WO2016140782A1 (en) 2015-03-04 2016-09-09 Modern Ideas LLC Stabilized calcium phosphate and methods of forming same
US9956314B2 (en) 2016-01-26 2018-05-01 Modern Ideas LLC Adhesive for use with bone and bone-like structures
US10383807B2 (en) * 2016-05-20 2019-08-20 The Procter & Gamble Company Regimen for providing smooth tooth feel
WO2018022553A1 (en) 2016-07-25 2018-02-01 Cerapedics, Inc. Peptide-coated calcium phosphate particles

Similar Documents

Publication Publication Date Title
USRE33161E (en) Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements
US4612053A (en) Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements
US4518430A (en) Dental resptorative cement pastes
USRE33221E (en) Dental restorative cement pastes
US5460803A (en) Methods and compositions for mineralizing and fluoridating calcified tissues
US6056930A (en) Methods and compositions for mineralizing and fluoridating calcified tissues
US5268167A (en) Methods and compositions for mineralizing and fluoridating calcified tissues
US5534244A (en) Methods and compositions for mineralizing and/or fluoridating calcified tissues with amorphous strontium compounds
US5525148A (en) Self-setting calcium phosphate cements and methods for preparing and using them
US5427768A (en) Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
US5342441A (en) Biologically compatible hardening material for dental or medical applications
JP3017536B2 (en) Calcium phosphate / hydroxyapatite precursor and method for producing and using the same
US6000341A (en) Methods and composition for mineralizing and fluoridating calcified tissues
Medvecky et al. Effect of tetracalcium phosphate/monetite toothpaste on dentin remineralization and tubule occlusion in vitro
Soni et al. Remineralizing agents in paediatric dentistry
US20040208835A1 (en) Remineralizing dental hygiene products
WO1996025914A1 (en) Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
KR20230091121A (en) Acceleration of tooth remineralization and bone regeneration using self-assembling peptides and amorphous calcium phosphate
CA2213689A1 (en) Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
MXPA97006443A (en) Carbonated solutions to treat, mineralize and fluorinate calcified tissues and methods for your

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: STRYKER TECHNOLOGIES CORPORATION, MICHIGAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOWMEDICA INC.;REEL/FRAME:009781/0191

Effective date: 19981202

AS Assignment

Owner name: BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIA

Free format text: SECURITY AGREEMENT;ASSIGNORS:STRYKER CORPORATION;STRYKER FAR EAST, INC.;REEL/FRAME:014137/0212

Effective date: 19981204

Owner name: BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIA

Free format text: SECURITY INTEREST;ASSIGNORS:STRYKER CORPORATION;STRYKER FAR EAST, INC.;STRYKER INTERNATIONAL INC.;AND OTHERS;REEL/FRAME:009817/0001

Effective date: 19981204

AS Assignment

Owner name: STRYKER CORPORATION, MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: STRYKER FAR EAST, INC., MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: STRYKER INTERNATIONAL, INC., MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: HOWMEDICA OSTEONICS CORPORATION, MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: PHYSIOTHERAPY ASSOCIATES, INC., MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: STRYKER PUERTO RICO INC., MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: STRYKER SALES CORPORATION, MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: STRYKER TECHNOLOGIES CORPORATION, MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: STRYKER FOREIGN HOLDCO, INC., MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: SMD CORPORATION, MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124

Owner name: HOWMEDICAL LEIBINGER, INC., MICHIGAN

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A. (F/K/A BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION);REEL/FRAME:012539/0557

Effective date: 20020124